{"gene":"IL6","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":1986,"finding":"IL-6 (originally identified as BSF-2) was cloned from human cDNA, revealing it is a novel interleukin of 184 amino acids that induces final maturation of B cells into immunoglobulin-secreting cells.","method":"cDNA cloning, structural analysis, and functional expression in B cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with functional validation, foundational paper with >2000 citations","pmids":["3491322"],"is_preprint":false},{"year":1987,"finding":"IL-6 (IFN-beta 2/BSF-2) was shown to be the monocyte-derived hepatocyte-stimulating factor that drives the major acute-phase protein response in liver cells, establishing the liver as a primary physiologic target of IL-6.","method":"Neutralizing antibody experiments, recombinant protein treatment of HepG2 cells and primary rat hepatocytes, Northern analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with recombinant protein plus antibody-blocking, replicated across cell types; >1700 citations","pmids":["2444978"],"is_preprint":false},{"year":1989,"finding":"IL-6 signaling requires its receptor (IL-6-R, 80 kDa) to trigger association with a second non-ligand-binding membrane glycoprotein, gp130; this association is temperature-dependent (occurs at 37°C but not 0°C) and a soluble IL-6-R lacking transmembrane/intracytoplasmic domains can associate with gp130 extracellularly and mediate IL-6 signaling (trans-signaling).","method":"Co-immunoprecipitation, binding assays, transfection of mutant receptors in murine cells","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — receptor association demonstrated by biochemical and functional assays with domain-deletion mutants; >1300 citations","pmids":["2788034"],"is_preprint":false},{"year":1989,"finding":"IL-1β stimulation of human endothelial cells markedly increases (10-15-fold) IL-6 production, confirmed by anti-IL-6 antibody inhibition of hybridoma growth factor activity and Northern blot analysis of IL-6 mRNA; IL-6 itself did not alter endothelial cell function (proliferation, procoagulant activity, prostacyclin, or PMN adhesion).","method":"Bioassay (HGF on 7TD1 cells), neutralizing antibodies, Northern blot, functional assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in a well-controlled study; >580 citations","pmids":["2783442"],"is_preprint":false},{"year":1990,"finding":"IL-6 is produced by osteoblasts in response to local bone-resorbing agents (IL-1α, IL-1β, TNF-α, LPS) and itself induces bone resorption by increasing osteoclast numbers, and acts cooperatively with IL-1α at suboptimal concentrations.","method":"RT-PCR/Northern blot for IL-6 mRNA, 45Ca release assay, osteoclast counting in histological sections","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays in primary cells and cell lines; >920 citations","pmids":["2121824"],"is_preprint":false},{"year":1990,"finding":"gp130 was molecularly cloned (918 amino acids, single transmembrane domain, extracellular fibronectin type III modules). gp130 alone does not bind IL-6 but co-transfection with IL-6-R cDNA generates high-affinity IL-6 binding sites. gp130 associates with the IL-6/soluble IL-6-R complex extracellularly and transduces the growth signal.","method":"cDNA cloning, binding assays, co-transfection experiments, growth signal transduction assay in IL-3-dependent cell line","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — molecular cloning with functional reconstitution; >1250 citations","pmids":["2261637"],"is_preprint":false},{"year":1991,"finding":"Oncostatin M (OncM) stimulates IL-6 production in human endothelial cells in a time- and dose-dependent manner (>10-fold at 6 h), associated with a 7-fold increase in IL-6 mRNA; IL-1α and TNF-α also induce IL-6 in these cells; TNF-α but not IL-1α synergizes with OncM for IL-6 production.","method":"Immunoassay (IL-6 ELISA), Northern blot, receptor binding assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple assays in a single study","pmids":["1918953"],"is_preprint":false},{"year":1994,"finding":"gp130 and LIF receptor β constitutively associate with JAK/TYK kinases (JAK1, JAK2, TYK2); ligand-induced dimerization of the receptor β components activates these kinases. The CNTF cytokine family receptors utilize all known members of the JAK-TYK family but induce distinct phosphorylation patterns.","method":"Co-immunoprecipitation, kinase activation assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — co-immunoprecipitation and kinase activation assays; >920 citations; established mechanistic basis of IL-6/gp130 signaling","pmids":["8272873"],"is_preprint":false},{"year":1996,"finding":"IL-6 induces VEGF expression in multiple cell lines (Northern blot); this induction is mediated not only by promoter DNA elements but also through specific motifs in the 5'-UTR of VEGF mRNA, suggesting IL-6 drives angiogenesis indirectly via VEGF induction.","method":"Northern blot analysis, transient transfection/reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — Northern blot plus functional transfection reporter assays; >890 citations","pmids":["8557680"],"is_preprint":false},{"year":1996,"finding":"In vivo, the soluble IL-6 receptor (sIL-6R) dramatically hypersensitizes cells to IL-6 by prolonging IL-6 plasma half-life and extending the acute phase response; the IL-6/sIL-6R complex (but not IL-6 alone) drives massive extramedullary hematopoiesis in liver and spleen, demonstrating a biologically distinct activity of the trans-signaling complex.","method":"Transgenic mouse models expressing human IL-6, human sIL-6R, or both; acute-phase protein measurements; histology","journal":"Immunology letters","confidence":"High","confidence_rationale":"Tier 2 — genetic/transgenic animal model with multiple functional readouts","pmids":["9052874"],"is_preprint":false},{"year":1999,"finding":"Repression of the IL-6 gene in MCF-7 breast carcinoma cells is associated with hypermethylation of the IL-6 gene; treatment with 5-aza-2'-deoxycytidine (a demethylating agent) restores IL-6 expression, establishing DNA methylation as a mechanism of IL-6 transcriptional repression.","method":"Northern blot, 5-aza-dC treatment, methylation analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological demethylation correlated with gene re-expression; single lab","pmids":["10329438"],"is_preprint":false},{"year":2000,"finding":"IL-6 produced by contracting skeletal muscle accounts for the exercise-induced rise in plasma IL-6: direct arterial-femoral venous difference measurements showed net IL-6 release only from the exercising (not resting) leg, with IL-6 production rates of ~6.8 ng/min per kg active muscle.","method":"Arterial-femoral venous difference measurements, ultrasound Doppler blood flow, ELISA","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 2 — direct measurement of net cytokine release from exercising muscle in vivo; >780 citations","pmids":["11080265"],"is_preprint":false},{"year":2001,"finding":"During turpentine-induced inflammation, CRH is required for normal ACTH response and for adrenal IL-6 expression. Loss of CRH paradoxically increases plasma IL-6 from non-adrenal sources, revealing that IL-6 release during inflammation is CRH-dependent and IL-6 can compensate for CRH deficiency effects on food intake.","method":"Crh−/− and Crh−/−/IL-6−/− mouse models, ELISA, in situ hybridization","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout combined with biochemical measurements","pmids":["11602623"],"is_preprint":false},{"year":2002,"finding":"IL-6 promotes Th2 differentiation by activating NFAT-mediated IL-4 transcription in naïve CD4+ T cells, while simultaneously inhibiting Th1 differentiation by upregulating SOCS-1 to interfere with IFNγ signaling — two independent molecular mechanisms.","method":"T cell differentiation assays, NFAT reporter assays, SOCS-1 expression analysis","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — two orthogonal mechanisms identified; single lab","pmids":["12431386"],"is_preprint":false},{"year":2003,"finding":"IL-6 induces anti-inflammatory responses in humans in vivo: recombinant IL-6 infusion (mimicking exercise levels, ~140 pg/mL) elevated plasma IL-1ra and IL-10, increased cortisol, and caused neutrocytosis and lymphopenia, without inducing TNF-α.","method":"Randomized human infusion study, ELISA cytokine measurements, leukocyte counts","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — controlled human intervention study demonstrating direct anti-inflammatory cytokine induction; >810 citations","pmids":["12857678"],"is_preprint":false},{"year":2003,"finding":"IL-6 induces insulin resistance in 3T3-L1 adipocytes through long-term inhibition of IRS-1, GLUT-4, and PPARγ gene transcription (reducing IRS-1 protein and insulin-stimulated glucose transport), without increasing pS-307 of IRS-1 or JNK activation (unlike TNF-α).","method":"Cell culture experiments with recombinant IL-6, Western blot, gene expression analysis, glucose transport assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal assays in single lab; >810 citations","pmids":["12952969"],"is_preprint":false},{"year":2004,"finding":"IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation via gp130: IL-6-knockout mice had increased mature DCs, and knockin mice with gp130 STAT3-signaling defects (gp130FxxQ/FxxQ) showed impaired IL-6-mediated suppression of LPS-induced DC maturation; STAT3 phosphorylation in DCs was regulated by IL-6 in vivo.","method":"IL-6 knockout and gp130 knockin mice, flow cytometry, T cell activation assays, STAT3 phosphorylation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic mouse models with defined pathway mutations; >400 citations","pmids":["15356132"],"is_preprint":false},{"year":2005,"finding":"IL-6 directly inhibits primary hepatocyte proliferation via a p21cip1-dependent mechanism (loss of p21cip1 abolishes IL-6-mediated inhibition), while indirectly stimulating proliferation by inducing HGF production from non-parenchymal cells; SOCS3 negatively regulates these effects.","method":"Primary mouse hepatocyte culture, p21cip1-knockout cells, co-culture assays, SOCS3+/- mice, in vivo liver regeneration assay","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout epistasis plus in vitro and in vivo assays; multiple orthogonal methods","pmids":["16288983"],"is_preprint":false},{"year":2005,"finding":"IL-6 rapidly increases AMPK activity in skeletal muscle, and IL-6-stimulated increases in fatty acid oxidation, basal/insulin-stimulated glucose uptake, and GLUT4 translocation to the plasma membrane are abrogated by dominant-negative AMPK, placing AMPK downstream of IL-6 signaling in muscle metabolism.","method":"IL-6 infusion/treatment of myotubes, AMPK activity assays, GLUT4 translocation, dominant-negative AMPK infection","journal":"Biochemical Society transactions","confidence":"Medium","confidence_rationale":"Tier 2 — dominant-negative epistasis in cell culture with functional metabolic readouts","pmids":["17956334"],"is_preprint":false},{"year":2006,"finding":"IL-6 directly regulates hepcidin expression through induction of STAT3, which then binds the hepcidin promoter; STAT3 is both necessary and sufficient for the IL-6 responsiveness of the hepcidin promoter.","method":"STAT3 knockout/siRNA, promoter reporter assays, ChIP, ELISA","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — promoter reporter assays plus ChIP plus loss-of-function; >750 citations","pmids":["16835372"],"is_preprint":false},{"year":2006,"finding":"Sleep enhances IL-6 trans-signaling capacity in healthy humans by selectively increasing concentrations of the proteolytically cleaved sIL-6R variant (not the differentially spliced form or mIL-6R density or sgp130), thus widening the spectrum of IL-6 target cells during sleep.","method":"Controlled sleep/wake study in humans, plasma sIL-6R/sgp130 measurement, mIL-6R flow cytometry, IL-6-producing monocyte analysis","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — controlled crossover design with multiple receptor measurements; single lab","pmids":["16912152"],"is_preprint":false},{"year":2009,"finding":"Persistent DNA damage signaling (DSBs marked by γH2AX foci) triggers IL-6 secretion as part of the senescence-associated secretory phenotype (SASP); this requires the DDR proteins ATM, NBS1, and CHK2 (but not p53 or pRb), and ATM-dependent IL-6 promotes cancer cell invasiveness in a paracrine manner.","method":"shRNA knockdown of DDR proteins, IL-6 ELISA, invasion assays, immunofluorescence","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic loss-of-function with functional readouts, replicated; >1750 citations","pmids":["19597488"],"is_preprint":false},{"year":2009,"finding":"Transient Src oncoprotein activation triggers an NF-κB-mediated inflammatory circuit that directly activates Lin28, which reduces let-7 microRNA levels; let-7 directly represses IL-6 translation, so its loss leads to elevated IL-6, which activates STAT3; STAT3 is necessary for cell transformation, and IL-6 activates NF-κB completing a positive feedback loop maintaining stable transformation.","method":"shRNA, reporter assays, overexpression, miRNA inhibitors, STAT3 inhibition, mammosphere formation assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal genetic and molecular tools establishing pathway; >1200 citations","pmids":["19878981"],"is_preprint":false},{"year":2011,"finding":"IL-6 classical signaling (via membrane-bound IL-6R → gp130 dimerization → JAK activation → SHP-2/Ras/MAPK and STAT3 phosphorylation → nuclear translocation) mediates regenerative/anti-inflammatory activities, while trans-signaling (via soluble IL-6R/gp130 complex) mediates pro-inflammatory responses.","method":"Review synthesizing biochemical pathway analysis; signaling domain experiments, chimeric receptor studies","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1-2 — synthesis of structural/biochemical pathway data from multiple labs; >2400 citations","pmids":["21296109"],"is_preprint":false},{"year":2011,"finding":"IL-6 trans-signaling (via soluble IL-6R) activates STAT3/SOCS3 in pancreatic ductal cells, and this signaling is required for progression of KrasG12D-driven pancreatic intraepithelial neoplasias (PanINs) to pancreatic ductal adenocarcinoma; myeloid cells are the source of IL-6 that activates pancreatic STAT3.","method":"Genetic mouse models (Kras G12D; IL-6 trans-signaling deficient; Socs3 knockout), immunohistochemistry, STAT3 phosphorylation analysis","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic mouse models with clear pathway epistasis; >710 citations","pmids":["21481788"],"is_preprint":false},{"year":2011,"finding":"IL-6 stimulates GLP-1 secretion from intestinal L cells and pancreatic α cells; in α cells, IL-6 increases GLP-1 production by upregulating proglucagon and prohormone convertase 1/3 expression, thereby improving insulin secretion and glycemia.","method":"IL-6 administration in mice/humans, GLP-1 ELISA, proglucagon/PC1-3 mRNA and protein expression, in vitro L cell and α cell experiments","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — mechanistic experiments in vitro and in vivo with molecular pathway identification; >730 citations","pmids":["22037645"],"is_preprint":false},{"year":2012,"finding":"IL-6 combined with TGF-β synergistically promotes proteasome-dependent FOXP3 protein degradation (post-translational), reducing Treg activity; MG132 (proteasome inhibitor) blocked this effect; IL-6/TGF-β upregulated IL-6R expression without affecting FOXP3 mRNA stability.","method":"FOXP3 overexpression model, Western blot, proteasome inhibitor (MG132), flow cytometry","journal":"International journal of clinical and experimental pathology","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, pharmacological inhibitor approach, mechanistic follow-up partial","pmids":["22977658"],"is_preprint":false},{"year":2014,"finding":"SOCS3 inhibits IL-6 signaling by binding simultaneously to gp130 and JAK1/JAK2/TYK2 (but not JAK3) via a 'GQM' motif in the JAK kinase domain; SOCS3 inhibits JAK activity in an ATP-independent manner by partially occluding the kinase substrate-binding groove with its kinase inhibitory region.","method":"Biochemical/structural studies, domain mutagenesis, binding assays","journal":"Seminars in immunology","confidence":"High","confidence_rationale":"Tier 1 — structural and biochemical mechanistic data from multiple labs; synthesis of structural evidence","pmids":["24418198"],"is_preprint":false},{"year":2015,"finding":"Tet2 selectively represses IL-6 transcription during inflammation resolution by recruiting Hdac2 to the Il6 promoter (independent of DNA methylation/hydroxymethylation); IκBζ targets Tet2 to the Il6 promoter; Tet2-deficient mice show elevated IL-6 and increased susceptibility to endotoxin shock and colitis.","method":"Tet2-knockout mice, ChIP assays, HDAC inhibitor experiments, Co-IP (Tet2-Hdac2), luciferase reporter assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including genetic models, ChIP, and Co-IP; >670 citations","pmids":["26287468"],"is_preprint":false},{"year":2017,"finding":"IL-6 enhances osteocyte-mediated osteoclastogenesis by activating the JAK2-STAT3 pathway to upregulate RANKL expression in osteocyte-like MLO-Y4 cells; inhibition of JAK2 with AG490 suppressed pJAK2, RANKL expression, and osteoclast differentiation.","method":"RT-PCR, Western blot, TRAP staining/osteoclast formation assay, JAK2 inhibitor AG490","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway inhibition plus gene expression in vitro; single lab","pmids":["28278513"],"is_preprint":false},{"year":2017,"finding":"Kdm6a (demethylase) promotes IL-6 transcription in macrophages by demethylating H3K27me3 at the IL-6 promoter in an enzymatic activity-dependent manner; this activity is downregulated via JNK pathway upon innate stimuli.","method":"Kdm6a knockdown/overexpression, ChIP-seq, H3K27me3 ChIP, enzymatic activity mutants in primary macrophages","journal":"Journal of autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq and enzymatic mutant experiments in primary cells; single lab","pmids":["28284523"],"is_preprint":false},{"year":2017,"finding":"Post-MI cardiac IL-6 is preferentially produced by cardiac fibroblasts; adenosine stimulates fibroblast IL-6 formation via adenosine receptor A2bR in a Gq-dependent manner; cardiac fibroblasts degrade extracellular ATP to adenosine but lack CD73, relying on T cell-derived adenosine for IL-6 regulation.","method":"Single-cell RNA-seq (mouse and human), RNAscope, qPCR, protein quantification in isolated cell types, A2bR pharmacology, CD4-CD73-/- mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — scRNA-seq plus genetic mouse model plus receptor pharmacology; validated in human data","pmids":["36943408"],"is_preprint":false},{"year":2021,"finding":"IL-6 activates autophagy through the IL-6/JAK2/BECN1 pathway: JAK2 directly phosphorylates BECN1 at Y333 upon IL-6 stimulation; Y333 phosphorylation is required for BECN1 activation and PI3KC3 complex formation, promoting chemotherapy resistance in colorectal cancer.","method":"Co-IP, in vitro kinase assay, site-directed mutagenesis (Y333), PI3KC3 complex immunoprecipitation, autophagy flux assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — direct kinase assay identifying phosphorylation site, mutagenesis validation, complex assembly assay","pmids":["34131122"],"is_preprint":false},{"year":2023,"finding":"IL-6 induces Csf1r (CSF1R) expression in Tet2-deficient macrophages through enhanced STAT3 binding to the Csf1r promoter; IL-6 receptor antibody treatment reverses Tet2 clonal hematopoiesis-accelerated atherosclerosis by reducing monocytosis, lesional macrophage burden, and CSF1R expression.","method":"IL-6R antibody treatment in Tet2 CH mice, ChIP for STAT3 at Csf1r promoter, CSF1R inhibitor (PLX3397), mouse and human macrophage experiments","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — ChIP identifying direct STAT3-promoter binding plus genetic and pharmacological validation in vivo","pmids":["37539077"],"is_preprint":false},{"year":2023,"finding":"In M2 macrophages, YY1 forms a liquid-liquid phase separation complex with p300, p65, and CEBPB that upregulates IL-6 through long-range chromatin interactions between an M2-specific IL-6 enhancer and the IL-6 promoter; IL-4/STAT6 pathway regulates YY1 expression.","method":"CRISPR-Cas9 KO, H3K27ac-ChIP-seq, YY1 ChIP-seq, LLPS assays, chromatin conformation (enhancer-promoter interaction), RNA-seq","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal genomic and biochemical methods including ChIP-seq and LLPS assays","pmids":["37094986"],"is_preprint":false}],"current_model":"IL-6, a 184-amino-acid four-helix bundle cytokine, signals by binding its membrane-bound IL-6Rα, triggering association with the signal-transducing subunit gp130, which dimerizes and constitutively-associated JAK kinases (JAK1, JAK2, TYK2) transphosphorylate gp130 tyrosines, engaging SHP-2/Ras/MAPK and STAT3 pathways; in trans-signaling, soluble IL-6Rα (shed by ADAM proteases) forms a complex with IL-6 that activates gp130 on cells lacking membrane IL-6Rα, broadly expanding IL-6's target cell repertoire; downstream STAT3 activation drives hepcidin expression, VEGF induction, dendritic cell maturation, Th17/Treg balance, osteoclastogenesis via RANKL upregulation, and pancreatic cancer progression, while SOCS3 terminates signaling by simultaneously binding JAK1/2/TYK2 and gp130; IL-6 transcription is regulated by epigenetic mechanisms including Tet2/Hdac2-mediated histone deacetylation (repression), Kdm6a-mediated H3K27me3 demethylation (activation), YY1 phase-separation complex-driven enhancer-promoter looping, and DNA methylation; JAK2 also directly phosphorylates BECN1 at Y333 to activate autophagy downstream of IL-6."},"narrative":{"teleology":[{"year":1986,"claim":"Molecular cloning of IL-6 (BSF-2) established it as a novel interleukin capable of driving B cell terminal differentiation into immunoglobulin-secreting cells, resolving the identity of a long-sought B cell stimulatory factor.","evidence":"cDNA cloning and functional expression in B cells","pmids":["3491322"],"confidence":"High","gaps":["No receptor identified","No signaling pathway known","Range of target cell types unknown"]},{"year":1987,"claim":"Demonstration that IL-6 is the monocyte-derived hepatocyte-stimulating factor driving the acute-phase protein response revealed the liver as a major physiologic target, expanding IL-6 function beyond B cell biology.","evidence":"Neutralizing antibody blockade and recombinant IL-6 treatment of HepG2 cells and primary hepatocytes","pmids":["2444978"],"confidence":"High","gaps":["Mechanism of hepatocyte signaling unknown","Receptor complex not yet defined"]},{"year":1989,"claim":"Discovery that IL-6Rα must recruit gp130 for signal transduction, and that a soluble IL-6Rα ectodomain can mediate this association extracellularly, established the two-receptor model and the concept of trans-signaling.","evidence":"Co-immunoprecipitation, binding assays, and transfection of transmembrane-deletion mutants in murine cells","pmids":["2788034"],"confidence":"High","gaps":["gp130 not yet cloned","Intracellular signaling cascade unknown","Physiologic relevance of trans-signaling in vivo unproven"]},{"year":1990,"claim":"Molecular cloning of gp130 and reconstitution of high-affinity IL-6 binding sites by co-transfection with IL-6Rα provided the structural basis for the signaling receptor complex and confirmed gp130 as the obligate signal transducer.","evidence":"cDNA cloning, co-transfection binding assays, and growth signal transduction assays in IL-3-dependent cells","pmids":["2261637"],"confidence":"High","gaps":["Kinases coupled to gp130 unknown","Downstream transcription factors not identified"]},{"year":1994,"claim":"Identification that gp130 constitutively associates with JAK1, JAK2, and TYK2, which are activated upon ligand-induced receptor dimerization, resolved the proximal kinase machinery of IL-6 signaling.","evidence":"Co-immunoprecipitation and kinase activation assays","pmids":["8272873"],"confidence":"High","gaps":["STAT activation downstream of JAKs not yet shown for IL-6 specifically","Negative regulators unknown"]},{"year":1996,"claim":"Two advances defined downstream effector outputs and trans-signaling physiology: IL-6 was shown to induce VEGF expression via promoter and 5′-UTR elements (linking IL-6 to angiogenesis), and transgenic mouse studies demonstrated that the IL-6/sIL-6R complex dramatically extends IL-6 half-life and drives extramedullary hematopoiesis not achievable by IL-6 alone.","evidence":"Northern blot/reporter assays for VEGF induction; transgenic mouse models with human IL-6 and sIL-6R","pmids":["8557680","9052874"],"confidence":"High","gaps":["STAT3 not yet directly linked to specific IL-6 gene targets","Mechanism of sIL-6R shedding unknown"]},{"year":1999,"claim":"Demonstration that IL-6 gene silencing in breast carcinoma cells is reversed by demethylation agents established DNA methylation as an epigenetic mechanism controlling IL-6 transcription.","evidence":"5-aza-2′-deoxycytidine treatment with Northern blot and methylation analysis in MCF-7 cells","pmids":["10329438"],"confidence":"Medium","gaps":["Specific CpG sites not mapped","Methyltransferases responsible not identified","Generalizability to non-cancer cells uncertain"]},{"year":2000,"claim":"Direct arterio-venous measurements across exercising human muscle proved that contracting skeletal muscle is a major source of circulating IL-6, establishing IL-6 as an exercise-released myokine.","evidence":"Arterial-femoral venous difference with Doppler blood flow and ELISA in exercising humans","pmids":["11080265"],"confidence":"High","gaps":["Intracellular signaling triggering muscle IL-6 release unknown","Metabolic targets of exercise-derived IL-6 not fully defined"]},{"year":2003,"claim":"Controlled human infusion studies showed IL-6 at exercise-relevant concentrations induces anti-inflammatory mediators (IL-1ra, IL-10, cortisol) without TNF-α, while parallel in vitro work demonstrated IL-6 causes insulin resistance in adipocytes through transcriptional suppression of IRS-1 and GLUT-4, revealing context-dependent metabolic and immune effects.","evidence":"Randomized human IL-6 infusion with cytokine ELISA; recombinant IL-6 treatment of 3T3-L1 adipocytes with Western blot and glucose transport assays","pmids":["12857678","12952969"],"confidence":"High","gaps":["Signaling pathway mediating adipocyte insulin resistance not fully delineated","In vivo adipose tissue effects not confirmed"]},{"year":2004,"claim":"Genetic dissection using IL-6−/− and gp130 STAT3-signaling-deficient knockin mice demonstrated that IL-6 regulates dendritic cell maturation in vivo through gp130-mediated STAT3 activation, placing STAT3 as a critical node for IL-6's immunomodulatory functions.","evidence":"IL-6 knockout and gp130FxxQ/FxxQ knockin mice with flow cytometry and STAT3 phosphorylation analysis","pmids":["15356132"],"confidence":"High","gaps":["Target genes downstream of STAT3 in DCs not cataloged","Contribution of trans- vs. classical signaling in DC regulation not resolved"]},{"year":2006,"claim":"ChIP and promoter-reporter studies showed IL-6 directly activates hepcidin transcription through STAT3 binding to the hepcidin promoter, establishing the molecular mechanism by which IL-6 drives hypoferremia of inflammation.","evidence":"STAT3 knockout/siRNA, ChIP at hepcidin promoter, reporter assays","pmids":["16835372"],"confidence":"High","gaps":["Relative contribution of IL-6 vs. BMP pathway to hepcidin not quantified","Role of trans-signaling at the hepcidin locus not tested"]},{"year":2009,"claim":"Two studies converged to place IL-6 at the center of oncogenic and senescence-associated feedback circuits: persistent DNA damage signaling (ATM/NBS1/CHK2-dependent) drives IL-6 secretion in the SASP to promote paracrine cancer invasiveness, while an NF-κB→Lin28→let-7 axis derepresses IL-6 translation, enabling IL-6/STAT3/NF-κB positive feedback that maintains Src-initiated transformation.","evidence":"shRNA knockdown of DDR proteins with invasion assays; miRNA inhibitors, reporter assays, and mammosphere formation","pmids":["19597488","19878981"],"confidence":"High","gaps":["Relative contribution of IL-6 vs. other SASP cytokines to invasiveness not isolated","In vivo validation of NF-κB/Lin28/let-7/IL-6 loop limited"]},{"year":2011,"claim":"Genetic epistasis in Kras-driven pancreatic cancer models demonstrated that myeloid-derived IL-6 activates STAT3/SOCS3 in ductal cells via trans-signaling and is required for PanIN progression to adenocarcinoma, providing the first in vivo genetic evidence that trans-signaling drives a specific cancer type.","evidence":"KrasG12D mice crossed with IL-6 trans-signaling–deficient and Socs3-knockout models; STAT3 phosphorylation immunohistochemistry","pmids":["21481788"],"confidence":"High","gaps":["Specific IL-6 target genes in ductal transformation not identified","Therapeutic targeting of trans-signaling not tested"]},{"year":2011,"claim":"IL-6 was shown to stimulate GLP-1 production from intestinal L cells and pancreatic α cells by upregulating proglucagon and prohormone convertase 1/3, linking IL-6 to incretin-mediated glucose homeostasis.","evidence":"IL-6 administration in mice and humans, GLP-1 ELISA, gene/protein expression in L cells and α cells","pmids":["22037645"],"confidence":"High","gaps":["Signaling intermediaries (STAT3 vs. MAPK) in L/α cells not resolved","Chronic vs. acute IL-6 effects on incretin axis not distinguished"]},{"year":2015,"claim":"Tet2 was identified as a selective transcriptional repressor of IL-6 that recruits Hdac2 to the IL-6 promoter independently of its DNA demethylase activity; IκBζ directs Tet2 to the locus, and Tet2 loss elevates IL-6 and worsens endotoxin shock and colitis.","evidence":"Tet2-knockout mice, Tet2–Hdac2 co-IP, ChIP at IL-6 promoter, HDAC inhibitor experiments, luciferase reporters","pmids":["26287468"],"confidence":"High","gaps":["Whether Tet2 represses IL-6 in non-myeloid cells unknown","Crystal structure of Tet2–Hdac2 complex lacking"]},{"year":2017,"claim":"Multiple layers of IL-6 regulation and effector function were refined: Kdm6a promotes IL-6 transcription by demethylating H3K27me3 at the promoter; IL-6 activates JAK2/STAT3 to upregulate RANKL in osteocytes, driving osteoclastogenesis; and SOCS3 terminates IL-6 signaling by simultaneously binding gp130 and JAK kinases to occlude the substrate-binding groove.","evidence":"ChIP-seq and enzymatic mutants in macrophages; JAK2 inhibitor in osteocyte-like cells; structural/biochemical domain analysis of SOCS3","pmids":["28284523","28278513","24418198"],"confidence":"High","gaps":["Relative contribution of Kdm6a vs. Tet2 in setting IL-6 transcription threshold not tested","Structural basis of SOCS3 specificity for gp130 over other cytokine receptors not fully resolved"]},{"year":2021,"claim":"Identification of BECN1 Y333 as a direct JAK2 phosphorylation substrate upon IL-6 stimulation revealed a non-canonical branch of IL-6 signaling that activates autophagy via PI3KC3 complex assembly, contributing to chemotherapy resistance.","evidence":"In vitro kinase assay, site-directed mutagenesis of BECN1 Y333, PI3KC3 complex immunoprecipitation, autophagy flux assays in colorectal cancer cells","pmids":["34131122"],"confidence":"High","gaps":["Whether BECN1 Y333 phosphorylation occurs downstream of trans- vs. classical signaling not tested","In vivo validation in animal tumor models limited"]},{"year":2023,"claim":"Two studies addressed IL-6 transcriptional control and therapeutic targeting: YY1 forms liquid-liquid phase separation condensates with p300/p65/CEBPB to drive enhancer–promoter looping at the IL-6 locus in M2 macrophages, and IL-6R antibody blockade reverses Tet2-deficiency-driven atherosclerosis by reducing STAT3 binding at the Csf1r promoter.","evidence":"CRISPR-KO, ChIP-seq, LLPS assays, and chromatin conformation studies; IL-6R antibody treatment in Tet2 CH mice with STAT3 ChIP at Csf1r","pmids":["37094986","37539077"],"confidence":"High","gaps":["Whether YY1 LLPS mechanism generalizes to other IL-6-producing cell types unknown","Long-term safety and efficacy of IL-6R blockade in clonal hematopoiesis patients not established"]},{"year":null,"claim":"Key unresolved questions include how classical and trans-signaling are quantitatively balanced in specific tissues, the full repertoire of direct STAT3 target genes in different IL-6-responsive cell types, and whether the JAK2/BECN1 autophagy axis operates in physiologic (non-cancer) contexts.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Tissue-specific quantitative balance of classical vs. trans-signaling","Complete catalog of direct IL-6/STAT3 target genes across cell types","Physiologic relevance of JAK2-BECN1 autophagy outside cancer"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[13,16,17,22,24,26]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,9,11,14,20,21]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,13,14,16,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,5,7,19,23,24,27,32]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[22,24,32]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[32]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[10,28,30,34]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[15,18,25]}],"complexes":["IL-6/IL-6Rα/gp130 hexameric signaling complex","IL-6/sIL-6Rα trans-signaling complex"],"partners":["IL6R","IL6ST","JAK1","JAK2","TYK2","STAT3","SOCS3","BECN1"],"other_free_text":[]},"mechanistic_narrative":"IL-6 is a pleiotropic four-helix-bundle cytokine that orchestrates acute-phase responses, immune cell differentiation, metabolic regulation, and tissue remodeling by engaging classical signaling through membrane-bound IL-6Rα/gp130 or trans-signaling through soluble IL-6Rα/gp130, both converging on JAK1/JAK2/TYK2-mediated activation of STAT3, SHP-2/Ras/MAPK, and AMPK pathways [PMID:2788034, PMID:8272873, PMID:21296109, PMID:17956334]. Classical signaling drives regenerative and anti-inflammatory programs—including hepatic acute-phase protein and hepcidin induction via STAT3 promoter binding, dendritic cell maturation control, and GLP-1 secretion from intestinal L cells—while trans-signaling preferentially mediates pro-inflammatory activities such as STAT3/SOCS3-dependent progression of Kras-driven pancreatic neoplasia and paracrine promotion of cancer cell invasiveness as part of the senescence-associated secretory phenotype [PMID:2444978, PMID:16835372, PMID:22037645, PMID:21481788, PMID:19597488]. IL-6 transcription is tightly regulated by epigenetic mechanisms including Tet2/Hdac2-mediated histone deacetylation at the IL-6 promoter, Kdm6a-catalyzed H3K27me3 demethylation, DNA methylation, and YY1/p300/p65/CEBPB phase-separation complexes that mediate enhancer–promoter looping [PMID:26287468, PMID:28284523, PMID:10329438, PMID:37094986]. Downstream, JAK2 directly phosphorylates BECN1 at Y333 to activate PI3KC3 complex-dependent autophagy, while SOCS3 terminates signaling by simultaneously engaging gp130 and JAK kinases to occlude the substrate-binding groove [PMID:34131122, PMID:24418198]."},"prefetch_data":{"uniprot":{"accession":"P05231","full_name":"Interleukin-6","aliases":["B-cell stimulatory factor 2","BSF-2","CTL differentiation factor","CDF","Hybridoma growth factor","Interferon beta-2","IFN-beta-2"],"length_aa":212,"mass_kda":23.7,"function":"Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable) IL6 is a potent inducer of the acute phase response. Rapid production of IL6 contributes to host defense during infection and tissue injury, but excessive IL6 synthesis is involved in disease pathology. In the innate immune response, is synthesized by myeloid cells, such as macrophages and dendritic cells, upon recognition of pathogens through toll-like receptors (TLRs) at the site of infection or tissue injury (Probable). In the adaptive immune response, is required for the differentiation of B cells into immunoglobulin-secreting cells. Plays a major role in the differentiation of CD4(+) T cell subsets. Essential factor for the development of T follicular helper (Tfh) cells that are required for the induction of germinal-center formation. Required to drive naive CD4(+) T cells to the Th17 lineage. Also required for proliferation of myeloma cells and the survival of plasmablast cells (By similarity) Acts as an essential factor in bone homeostasis and on vessels directly or indirectly by induction of VEGF, resulting in increased angiogenesis activity and vascular permeability (PubMed:12794819, PubMed:17075861). Induces, through 'trans-signaling' and synergistically with IL1B and TNF, the production of VEGF (PubMed:12794819). Involved in metabolic controls, is discharged into the bloodstream after muscle contraction increasing lipolysis and improving insulin resistance (PubMed:20823453). 'Trans-signaling' in central nervous system also regulates energy and glucose homeostasis (By similarity). Mediates, through GLP-1, crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand (By similarity). Also acts as a myokine (Probable). Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity). Also has a pivotal role in iron metabolism by regulating HAMP/hepcidin expression upon inflammation or bacterial infection (PubMed:15124018). Through activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced epithelial regeneration (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P05231/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL6","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL6","total_profiled":1310},"omim":[{"mim_id":"621409","title":"AUTOINFLAMMATION AND AUTOIMMUNITY, SYSTEMIC, WITH IMMUNE DYSREGULATION 2; AIAISD2","url":"https://www.omim.org/entry/621409"},{"mim_id":"621401","title":"DEAH-BOX HELICASE 35; DHX35","url":"https://www.omim.org/entry/621401"},{"mim_id":"621142","title":"CHROMOSOME 15 OPEN READING FRAME 39; C15ORF39","url":"https://www.omim.org/entry/621142"},{"mim_id":"621096","title":"IMMUNODEFICIENCY 132B; IMD132B","url":"https://www.omim.org/entry/621096"},{"mim_id":"621030","title":"AUTOINFLAMMATION, PANNICULITIS, AND DERMATOSIS SYNDROME, AUTOSOMAL DOMINANT; AIPDSA","url":"https://www.omim.org/entry/621030"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":187.7},{"tissue":"lung","ntpm":140.6},{"tissue":"urinary bladder","ntpm":256.4}],"url":"https://www.proteinatlas.org/search/IL6"},"hgnc":{"alias_symbol":["IL-6","BSF2","HGF","HSF"],"prev_symbol":["IFNB2"]},"alphafold":{"accession":"P05231","domains":[{"cath_id":"1.20.1250.10","chopping":"48-209","consensus_level":"high","plddt":93.0108,"start":48,"end":209}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05231","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05231-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05231-F1-predicted_aligned_error_v6.png","plddt_mean":85.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL6","jax_strain_url":"https://www.jax.org/strain/search?query=IL6"},"sequence":{"accession":"P05231","fasta_url":"https://rest.uniprot.org/uniprotkb/P05231.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05231/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05231"}},"corpus_meta":[{"pmid":"25190079","id":"PMC_25190079","title":"IL-6 in inflammation, immunity, and disease.","date":"2014","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/25190079","citation_count":3581,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25898198","id":"PMC_25898198","title":"IL-6 as a keystone cytokine in health and disease.","date":"2015","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25898198","citation_count":1874,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2121824","id":"PMC_2121824","title":"IL-6 is produced by osteoblasts and induces bone resorption.","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2121824","citation_count":925,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26867490","id":"PMC_26867490","title":"IL-6 pathway in the liver: From physiopathology to therapy.","date":"2016","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/26867490","citation_count":705,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12431386","id":"PMC_12431386","title":"The two faces of IL-6 on Th1/Th2 differentiation.","date":"2002","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12431386","citation_count":695,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26287468","id":"PMC_26287468","title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26287468","citation_count":671,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29499302","id":"PMC_29499302","title":"Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters.","date":"2018","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29499302","citation_count":585,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2783442","id":"PMC_2783442","title":"IL-1 stimulates IL-6 production in endothelial cells.","date":"1989","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2783442","citation_count":581,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24602448","id":"PMC_24602448","title":"The two faces of IL-6 in the tumor microenvironment.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24602448","citation_count":560,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27381687","id":"PMC_27381687","title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm.","date":"2016","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/27381687","citation_count":497,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32327746","id":"PMC_32327746","title":"Translating IL-6 biology into effective treatments.","date":"2020","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/32327746","citation_count":483,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15356132","id":"PMC_15356132","title":"IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15356132","citation_count":401,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14609022","id":"PMC_14609022","title":"Searching for the exercise factor: is IL-6 a candidate?","date":"2003","source":"Journal of muscle research and cell motility","url":"https://pubmed.ncbi.nlm.nih.gov/14609022","citation_count":394,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12110143","id":"PMC_12110143","title":"The paradigm of IL-6: from basic science to medicine.","date":"2002","source":"Arthritis research","url":"https://pubmed.ncbi.nlm.nih.gov/12110143","citation_count":368,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31992476","id":"PMC_31992476","title":"A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors.","date":"2020","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31992476","citation_count":330,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25616716","id":"PMC_25616716","title":"Versatile functions for IL-6 in metabolism and cancer.","date":"2015","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25616716","citation_count":298,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28778870","id":"PMC_28778870","title":"Interleukin (IL-6) Immunotherapy.","date":"2018","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/28778870","citation_count":295,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23532539","id":"PMC_23532539","title":"The role of intratumoral and systemic IL-6 in breast cancer.","date":"2013","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/23532539","citation_count":286,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25649043","id":"PMC_25649043","title":"The varying faces of IL-6: From cardiac protection to cardiac failure.","date":"2015","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/25649043","citation_count":264,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25172494","id":"PMC_25172494","title":"Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25172494","citation_count":252,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25478789","id":"PMC_25478789","title":"IL-6 stimulates intestinal epithelial proliferation and repair after injury.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25478789","citation_count":217,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28278513","id":"PMC_28278513","title":"IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28278513","citation_count":199,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34131122","id":"PMC_34131122","title":"IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34131122","citation_count":198,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2786029","id":"PMC_2786029","title":"Regulation of the expression of IL-6 in human monocytes.","date":"1989","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2786029","citation_count":192,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27330885","id":"PMC_27330885","title":"Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6.","date":"2016","source":"SpringerPlus","url":"https://pubmed.ncbi.nlm.nih.gov/27330885","citation_count":186,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24418198","id":"PMC_24418198","title":"Inhibition of IL-6 family cytokines by SOCS3.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24418198","citation_count":169,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27734409","id":"PMC_27734409","title":"Regulation of IL-6 in Immunity and Diseases.","date":"2016","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/27734409","citation_count":164,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1918953","id":"PMC_1918953","title":"Regulation of IL-6 expression by oncostatin M.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1918953","citation_count":154,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29280266","id":"PMC_29280266","title":"Senescence promotes in vivo reprogramming through p16INK4a and IL-6.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/29280266","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25722296","id":"PMC_25722296","title":"Factors Associated With Plasma IL-6 Levels During HIV Infection.","date":"2015","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25722296","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17024100","id":"PMC_17024100","title":"Functional implications of the IL-6 signaling pathway in keloid pathogenesis.","date":"2006","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17024100","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17956334","id":"PMC_17956334","title":"IL-6 signalling in exercise and disease.","date":"2007","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17956334","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34711820","id":"PMC_34711820","title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34711820","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34103524","id":"PMC_34103524","title":"Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34103524","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11602623","id":"PMC_11602623","title":"Corticotropin-releasing hormone regulates IL-6 expression during inflammation.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11602623","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23994594","id":"PMC_23994594","title":"Brain IL-6 and autism.","date":"2013","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23994594","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28507168","id":"PMC_28507168","title":"Nutritional interventions and the IL-6 response to exercise.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28507168","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37633799","id":"PMC_37633799","title":"The exercise IL-6 enigma in cancer.","date":"2023","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/37633799","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37094986","id":"PMC_37094986","title":"YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37094986","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18093689","id":"PMC_18093689","title":"Inflammation, HCC and sex: IL-6 in the centre of the triangle.","date":"2007","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/18093689","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35924148","id":"PMC_35924148","title":"IL-6: The Link Between Inflammation, Immunity and Breast Cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35924148","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19365268","id":"PMC_19365268","title":"Clinical value of blocking IL-6 receptor.","date":"2009","source":"Current opinion in rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/19365268","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24067382","id":"PMC_24067382","title":"IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions.","date":"2013","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24067382","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16912152","id":"PMC_16912152","title":"Sleep enhances IL-6 trans-signaling in humans.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/16912152","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16129909","id":"PMC_16129909","title":"Role of IL-6 in the neural stem cell differentiation.","date":"2005","source":"Clinical reviews in allergy & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16129909","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26289430","id":"PMC_26289430","title":"Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis.","date":"2015","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/26289430","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24613573","id":"PMC_24613573","title":"The IL-6 feed-forward loop: a driver of tumorigenesis.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24613573","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34405445","id":"PMC_34405445","title":"Role of IL-6 in dendritic cell functions.","date":"2021","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/34405445","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17428894","id":"PMC_17428894","title":"Sex differences in monocyte expression of IL-6: role of autonomic mechanisms.","date":"2007","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17428894","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11422521","id":"PMC_11422521","title":"TNFalpha and IL-6 are mediators in the blistering process of pemphigus.","date":"2001","source":"International journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/11422521","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11034416","id":"PMC_11034416","title":"Endogenous and exogenous IL-6 inhibit aeroallergen-induced Th2 inflammation.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11034416","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20148256","id":"PMC_20148256","title":"Involvement of IL-17F via the induction of IL-6 in psoriasis.","date":"2010","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/20148256","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17448042","id":"PMC_17448042","title":"Polymorphisms in the CD14 and IL-6 genes associated with periodontal disease.","date":"2007","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/17448042","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28284523","id":"PMC_28284523","title":"Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages.","date":"2017","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28284523","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16288983","id":"PMC_16288983","title":"IL-6 modulates hepatocyte proliferation via induction of HGF/p21cip1: regulation by SOCS3.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16288983","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27082319","id":"PMC_27082319","title":"Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes.","date":"2016","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/27082319","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16229816","id":"PMC_16229816","title":"Induction of IL-6 expression by mechanical stress in the trabecular meshwork.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16229816","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24633552","id":"PMC_24633552","title":"IL-6 regulates adipose deposition and homeostasis in lymphedema.","date":"2014","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24633552","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35340805","id":"PMC_35340805","title":"Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35340805","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37539077","id":"PMC_37539077","title":"Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis.","date":"2023","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/37539077","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25547486","id":"PMC_25547486","title":"Upregulation of TLRs and IL-6 as a marker in human colorectal cancer.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25547486","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21289639","id":"PMC_21289639","title":"IL-23-mediated epidermal hyperplasia is dependent on IL-6.","date":"2011","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21289639","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25376720","id":"PMC_25376720","title":"Notch signaling induces root resorption via RANKL and IL-6 from hPDL cells.","date":"2014","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/25376720","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21427577","id":"PMC_21427577","title":"The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.","date":"2011","source":"Current opinion in rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/21427577","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34099967","id":"PMC_34099967","title":"IL-6 Directed Therapy in Transplantation.","date":"2021","source":"Current transplantation reports","url":"https://pubmed.ncbi.nlm.nih.gov/34099967","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10790864","id":"PMC_10790864","title":"Expression of IL-6 in the ischemic penumbra.","date":"2000","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/10790864","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25807183","id":"PMC_25807183","title":"The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6.","date":"2015","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25807183","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39589436","id":"PMC_39589436","title":"IL-6 and Cardiovascular Risk: A Narrative Review.","date":"2024","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/39589436","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29276788","id":"PMC_29276788","title":"A Role for Soluble IL-6 Receptor in Osteoarthritis.","date":"2017","source":"Journal of functional morphology and kinesiology","url":"https://pubmed.ncbi.nlm.nih.gov/29276788","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17384473","id":"PMC_17384473","title":"Essential role of IL-6 signaling pathway in keloid pathogenesis.","date":"2007","source":"Journal of Nippon Medical School = Nippon Ika Daigaku zasshi","url":"https://pubmed.ncbi.nlm.nih.gov/17384473","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36943408","id":"PMC_36943408","title":"IL-6 in the infarcted heart is preferentially formed by fibroblasts and modulated by purinergic signaling.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36943408","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27497026","id":"PMC_27497026","title":"Revisiting IL-6 antagonism in multiple myeloma.","date":"2016","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/27497026","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26474486","id":"PMC_26474486","title":"AMPK Activation by A-769662 Controls IL-6 Expression in Inflammatory Arthritis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26474486","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18757054","id":"PMC_18757054","title":"Acrolein, IL-6 and CRP as markers of silent brain infarction.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18757054","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18473869","id":"PMC_18473869","title":"The blockade of IL-6 signaling in rational drug design.","date":"2008","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/18473869","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35527168","id":"PMC_35527168","title":"IL-6 and its role in IgA nephropathy development.","date":"2022","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35527168","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23830919","id":"PMC_23830919","title":"IL-6 is produced by adipose-derived stromal cells and promotes osteogenesis.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23830919","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21302967","id":"PMC_21302967","title":"Blockade of IL-6 secretion pathway by the sesquiterpenoid atractylenolide III.","date":"2011","source":"Journal of natural products","url":"https://pubmed.ncbi.nlm.nih.gov/21302967","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34022535","id":"PMC_34022535","title":"Therapeutic targeting of IL-6 trans-signaling.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/34022535","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34044328","id":"PMC_34044328","title":"Inborn errors of IL-6 family cytokine responses.","date":"2021","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34044328","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26204410","id":"PMC_26204410","title":"Relationship among IL-6, LDL cholesterol and lipid peroxidation.","date":"2015","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26204410","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29791472","id":"PMC_29791472","title":"Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29791472","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22977658","id":"PMC_22977658","title":"Synergy between IL-6 and TGF-β signaling promotes FOXP3 degradation.","date":"2012","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22977658","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10329438","id":"PMC_10329438","title":"Repression of the IL-6 gene is associated with hypermethylation.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10329438","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33393227","id":"PMC_33393227","title":"Role of Serum IL-6 in Neuropsychiatric Systemic lupus Erythematosus.","date":"2021","source":"ACR open rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/33393227","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30132351","id":"PMC_30132351","title":"AA amyloidosis - Benefits and prospects of IL-6 inhibitors.","date":"2018","source":"Modern rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/30132351","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24859008","id":"PMC_24859008","title":"I-BET151 selectively regulates IL-6 production.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24859008","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9052874","id":"PMC_9052874","title":"The function of the soluble IL-6 receptor in vivo.","date":"1996","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/9052874","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30342072","id":"PMC_30342072","title":"Blockade of IL-6 signaling in neuromyelitis optica.","date":"2018","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/30342072","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31572184","id":"PMC_31572184","title":"Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31572184","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24397394","id":"PMC_24397394","title":"Circulating galanin and IL-6 concentrations in gestational diabetes mellitus.","date":"2014","source":"Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24397394","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17982069","id":"PMC_17982069","title":"IL-6 contributes to the expression of RAGs in human mature B cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17982069","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33482848","id":"PMC_33482848","title":"Chronic exposure to IL-6 induces a desensitized phenotype of the microglia.","date":"2021","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/33482848","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22150003","id":"PMC_22150003","title":"Immunotherapeutic implication of IL-6 blockade.","date":"2012","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/22150003","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27863335","id":"PMC_27863335","title":"IL-6 trans-signaling is another pathway to upregulate Osteopontin.","date":"2016","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/27863335","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31763378","id":"PMC_31763378","title":"Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.","date":"2019","source":"Bone reports","url":"https://pubmed.ncbi.nlm.nih.gov/31763378","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19783680","id":"PMC_19783680","title":"MAIL regulates human monocyte IL-6 production.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19783680","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31424261","id":"PMC_31424261","title":"Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib.","date":"2019","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/31424261","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36965369","id":"PMC_36965369","title":"Inhibition of IL-6 methylation by Saikosaponin C regulates neuroinflammation to alleviate depression.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36965369","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29626088","id":"PMC_29626088","title":"Granulocytes Are Unresponsive to IL-6 Due to an Absence of gp130.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29626088","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21296109","id":"PMC_21296109","title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21296109","citation_count":2469,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29405201","id":"PMC_29405201","title":"Targeting the IL-6/JAK/STAT3 signalling axis in cancer.","date":"2018","source":"Nature reviews. Clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29405201","citation_count":2427,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19188531","id":"PMC_19188531","title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.","date":"2009","source":"Psychosomatic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19188531","citation_count":2179,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3491322","id":"PMC_3491322","title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3491322","citation_count":2129,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19597488","id":"PMC_19597488","title":"Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion.","date":"2009","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19597488","citation_count":1754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2444978","id":"PMC_2444978","title":"Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2444978","citation_count":1737,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2788034","id":"PMC_2788034","title":"Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2788034","citation_count":1362,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11984595","id":"PMC_11984595","title":"Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.","date":"2002","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11984595","citation_count":1339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2261637","id":"PMC_2261637","title":"Molecular cloning and expression of an IL-6 signal transducer, gp130.","date":"1990","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2261637","citation_count":1259,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19878981","id":"PMC_19878981","title":"An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19878981","citation_count":1202,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12606524","id":"PMC_12606524","title":"Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12606524","citation_count":1167,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8272873","id":"PMC_8272873","title":"Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8272873","citation_count":929,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8557680","id":"PMC_8557680","title":"Interleukin 6 induces the expression of vascular endothelial growth factor.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8557680","citation_count":896,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23136554","id":"PMC_23136554","title":"Interleukin-6, a major cytokine in the central nervous system.","date":"2012","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23136554","citation_count":850,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26033244","id":"PMC_26033244","title":"Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α.","date":"2015","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26033244","citation_count":836,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12840146","id":"PMC_12840146","title":"Chronic stress and age-related increases in the proinflammatory cytokine IL-6.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12840146","citation_count":835,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12952969","id":"PMC_12952969","title":"Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12952969","citation_count":816,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12857678","id":"PMC_12857678","title":"IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans.","date":"2003","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12857678","citation_count":812,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11080265","id":"PMC_11080265","title":"Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6.","date":"2000","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11080265","citation_count":780,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15955385","id":"PMC_15955385","title":"Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6.","date":"2004","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/15955385","citation_count":773,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16835372","id":"PMC_16835372","title":"Interleukin-6 induces hepcidin expression through STAT3.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16835372","citation_count":759,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32425269","id":"PMC_32425269","title":"Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32425269","citation_count":736,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22037645","id":"PMC_22037645","title":"Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.","date":"2011","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22037645","citation_count":730,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15780075","id":"PMC_15780075","title":"IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly.","date":"2005","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/15780075","citation_count":715,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21481788","id":"PMC_21481788","title":"Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/21481788","citation_count":712,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32344321","id":"PMC_32344321","title":"Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.","date":"2020","source":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","url":"https://pubmed.ncbi.nlm.nih.gov/32344321","citation_count":707,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18784373","id":"PMC_18784373","title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18784373","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45719,"output_tokens":4580,"usd":0.102929},"stage2":{"model":"claude-opus-4-6","input_tokens":8131,"output_tokens":3755,"usd":0.201795},"total_usd":0.723548,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59376,"output_tokens":7983,"usd":0.148936},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12145,"output_tokens":4768,"usd":0.269888}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"Tet2 recruits Hdac2 to the Il6 promoter to repress IL-6 transcription via histone deacetylation during inflammation resolution, independent of DNA methylation/hydroxymethylation. IκBζ mediates specific targeting of Tet2 to the Il6 promoter.\",\n      \"method\": \"Chromatin immunoprecipitation, Tet2 knockout mice, loss-of-function experiments with defined phenotype (increased IL-6, susceptibility to endotoxin shock and colitis)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (ChIP, KO mice, phenotypic readouts) in a single rigorous study\",\n      \"pmids\": [\"26287468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOCS3 inhibits IL-6 signaling by binding simultaneously to gp130 and JAK1/JAK2/TYK2, partially occluding the kinase substrate-binding groove via its kinase inhibitory region in an ATP-independent manner. Specificity for JAK1/2/TYK2 but not JAK3 is determined by a 'GQM' motif in the kinase domain.\",\n      \"method\": \"Biochemical binding assays, structural studies, mutagenesis\",\n      \"journal\": \"Seminars in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural and biochemical reconstitution with mutagenesis defining the mechanism\",\n      \"pmids\": [\"24418198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-6 signals through gp130-STAT3 to maintain dendritic cells in an immature state in vivo; loss of IL-6 or STAT3 signaling downstream of gp130 leads to increased numbers of mature DCs and enhanced DC-mediated T cell activation.\",\n      \"method\": \"IL-6 knockout mice, gp130 knockin mice with selective signaling defects (gp130F759/F759 and gp130FxxQ/FxxQ), STAT3 phosphorylation analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple knockin/knockout models and defined cellular phenotype\",\n      \"pmids\": [\"15356132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-6 activates autophagy through JAK2-mediated phosphorylation of BECN1 at Y333, promoting PI3KC3 complex formation; this pathway drives chemotherapy resistance in colorectal cancer.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (Y333), autophagy flux assays, loss-of-function experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct phosphorylation site identified by mutagenesis with functional validation of PI3KC3 complex formation\",\n      \"pmids\": [\"34131122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-6 promotes Th2 differentiation by activating NFAT-mediated IL-4 production in naïve CD4+ T cells, and independently inhibits Th1 differentiation by upregulating SOCS1 to interfere with IFN-γ signaling.\",\n      \"method\": \"In vitro T cell differentiation assays, NFAT reporter assays, SOCS1 expression analysis, cytokine neutralization\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two independent molecular mechanisms identified with functional assays in a single study\",\n      \"pmids\": [\"12431386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The soluble IL-6 receptor (sIL-6R) forms a complex with IL-6 that activates gp130 on cells lacking membrane-bound IL-6R (trans-signaling), resulting in distinct biological effects including extramedullary hematopoiesis not seen with IL-6 alone; sIL-6R prolongs IL-6 plasma half-life and hypersensitizes animals to IL-6.\",\n      \"method\": \"Transgenic mice expressing human IL-6 and/or human soluble IL-6R, acute phase protein measurements, histological analysis\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic dissection with multiple transgenic models demonstrating distinct biological outcomes for sIL-6R vs IL-6 alone\",\n      \"pmids\": [\"9052874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Sleep enhances IL-6 trans-signaling by selectively increasing concentrations of the proteolytic cleavage-derived soluble IL-6 receptor (sIL-6R) variant in plasma, without affecting membrane-bound IL-6R density or IL-6-producing monocyte numbers.\",\n      \"method\": \"Repeated blood sampling in controlled sleep-wake cycles in humans, flow cytometry, ELISA for sIL-6R variants (PC vs DS)\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct measurement in controlled human experiment distinguishing receptor variants\",\n      \"pmids\": [\"16912152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-6 enhances osteocyte-mediated osteoclastogenesis by activating the JAK2-STAT3 pathway to upregulate RANKL expression (mRNA and protein) and increase the RANKL/OPG ratio; JAK2 inhibition blocks these effects.\",\n      \"method\": \"In vitro treatment of osteocyte-like MLO-Y4 cells with IL-6/IL-6R, qRT-PCR, Western blot, co-culture osteoclastogenesis assay, JAK2 inhibitor (AG490)\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway defined with pharmacological inhibition and multiple readouts\",\n      \"pmids\": [\"28278513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-6 directly inhibits hepatocyte proliferation via p21cip1 induction; disruption of p21cip1 abolishes IL-6-mediated inhibition. IL-6 also indirectly enhances hepatocyte proliferation by stimulating nonparenchymal cells to produce HGF. SOCS3 negatively regulates both p21cip1 induction and liver regeneration.\",\n      \"method\": \"Primary mouse hepatocyte culture, p21cip1 knockout, co-culture experiments, SOCS3 heterozygous mice, liver regeneration assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function (p21cip1 KO) confirms mechanism, supported by multiple cell-type experiments\",\n      \"pmids\": [\"16288983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IL-6 promotes expression of RAG1 and RAG2 recombinases in mature human B cells following BCR/CD40 co-engagement, and also impedes BCR-mediated termination of RAG gene expression; neutralization of IL-6 or its receptor blocks RAG expression.\",\n      \"method\": \"IL-6 neutralization, IL-6R blocking antibodies, RAG1/2 expression assays in peripheral and tonsil B cells, IL-6/IL-6R upregulation analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking and neutralization with defined molecular readout (RAG expression)\",\n      \"pmids\": [\"17982069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IL-6 signals through STAT3 to promote osteogenic differentiation of adipose-derived stromal cells (ASCs); STAT3 binds directly to the osterix promoter to drive osterix expression during IL-6-stimulated osteogenesis.\",\n      \"method\": \"siRNA-mediated STAT3 knockdown, STAT3 overexpression, STAT3 inhibitor, chromatin immunoprecipitation (ChIP) of STAT3 at osterix promoter\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP directly shows STAT3 binding at target promoter; supported by gain/loss-of-function\",\n      \"pmids\": [\"23830919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Demethylase Kdm6a promotes IL-6 transcription in macrophages by demethylating H3K27me3 at the IL-6 promoter in a demethylase activity-dependent manner during innate immune responses.\",\n      \"method\": \"Kdm6a knockdown in primary macrophages, ChIP for H3K27me3 at IL-6 promoter, demethylase activity-deficient mutant\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP with enzymatic mutant confirms epigenetic mechanism\",\n      \"pmids\": [\"28284523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MAIL (IκBζ) binds the p50 subunit of NF-κB and increases IL-6 promoter activity in a C/EBPβ, NF-κB, and AP-1-dependent manner; siRNA knockdown of MAIL significantly decreases IL-6 production in human monocytes and THP-1 cells.\",\n      \"method\": \"Co-immunoprecipitation (MAIL-p50), IL-6 luciferase promoter assay, siRNA knockdown, primary human monocyte IL-6 ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assay plus functional promoter and siRNA knockdown evidence\",\n      \"pmids\": [\"19783680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Post-myocardial infarction IL-6 is preferentially produced by cardiac fibroblasts; adenosine stimulates fibroblast IL-6 production via the A2bR receptor in a Gq-dependent manner, with T cell-derived adenosine controlling this process through purinergic cooperation.\",\n      \"method\": \"Single-cell RNA-seq (mouse and human hearts), RNAscope, quantitative PCR, conditional knockout mice (CD4-CD73-/-), adenosine receptor pharmacology\",\n      \"journal\": \"Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including scRNA-seq in two species plus functional genetic model\",\n      \"pmids\": [\"36943408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Repression of the IL-6 gene in MCF-7 breast carcinoma cells is associated with hypermethylation of the IL-6 gene; treatment with the demethylating agent 5-aza-2'-deoxycytidine restores IL-6 expression, correlating with promoter hypomethylation.\",\n      \"method\": \"5-aza-2'-deoxycytidine treatment, methylation analysis, Northern blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pharmacological demethylation plus methylation analysis\",\n      \"pmids\": [\"10329438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-6 inhibits aeroallergen-induced Th2 airway inflammation; IL-6-deficient mice show exaggerated eosinophilia and elevated IL-4/IL-5/IL-13, while IL-6-overexpressing transgenic mice show diminished Th2 inflammation and reduced airway responsiveness, independent of IFN-γ regulation.\",\n      \"method\": \"IL-6 knockout and transgenic (CC10-IL-6) mice, OVA sensitization/challenge model, BAL cytokine measurement, airway responsiveness testing\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function genetic models with defined immunological phenotype\",\n      \"pmids\": [\"11034416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Granulocytes are unresponsive to IL-6 because they lack expression of gp130 (the signal-transducing subunit), despite expressing membrane-bound IL-6Rα; gp130 expression is lost during granulocyte maturation from granulocyte-monocyte progenitors.\",\n      \"method\": \"Flow cytometry for gp130 expression, STAT3/STAT1 phosphorylation assays in mouse and human granulocytes after IL-6 stimulation, comparison with progenitor cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assays in mouse and human cells with mechanistic explanation (gp130 absence)\",\n      \"pmids\": [\"29626088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-6 induces CSF1R (M-CSF receptor) expression in Tet2-deficient macrophages through enhanced STAT3 binding to the Csf1r promoter, increasing macrophage survival and promoting atherosclerosis; IL-6 receptor antibody treatment reverses this.\",\n      \"method\": \"ChIP for STAT3 at Csf1r promoter in Tet2-deficient macrophages, IL-6R antibody treatment, CSF1R inhibitor (PLX3397), atherosclerosis mouse model\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP defines direct transcriptional mechanism; confirmed by pharmacological and genetic intervention\",\n      \"pmids\": [\"37539077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The combination of TGF-β and IL-6 synergistically promotes FOXP3 protein degradation via the proteasome in T cells, while upregulating IL-6R expression; this is independent of effects on FOXP3 mRNA stability.\",\n      \"method\": \"Proteasome inhibitor (MG132) rescue assay, IL-6R expression analysis, FOXP3 overexpression model\",\n      \"journal\": \"International journal of clinical and experimental pathology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pharmacological inhibitor rescue without direct ubiquitination assay\",\n      \"pmids\": [\"22977658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In vivo reprogramming by OSKM requires IL-6 produced by senescent cells in a p16INK4a-dependent manner; Il6-mutant tissues are impaired in undergoing reprogramming, establishing IL-6 as a required paracrine factor for reprogramming.\",\n      \"method\": \"Il6-mutant mice, Ink4a/Arf null mice, p53-null mice, in vivo OSKM reprogramming model, IL-6 measurement\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function (Il6 mutant) with defined mechanistic pathway through p16INK4a-senescence axis\",\n      \"pmids\": [\"29280266\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-6 signals through a hexameric receptor complex (IL-6/IL-6Rα/gp130 dimer) via classical (membrane IL-6Rα) or trans-signaling (soluble IL-6Rα) modes, activating JAK1/JAK2/TYK2–STAT3 and Ras–MAPK pathways; SOCS3 terminates signaling by simultaneously binding gp130 and JAKs to occlude their substrate groove; transcription of the IL-6 gene is epigenetically regulated by Tet2/Hdac2-mediated histone deacetylation (repression) and Kdm6a-mediated H3K27me3 demethylation (activation); downstream, IL-6/JAK2 directly phosphorylates BECN1-Y333 to activate autophagy, induces RANKL/CSF1R via STAT3, and promotes Th2 differentiation via NFAT while suppressing Th1 via SOCS1 upregulation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"IL-6 (originally identified as BSF-2) was cloned from human cDNA, revealing it is a novel interleukin of 184 amino acids that induces final maturation of B cells into immunoglobulin-secreting cells.\",\n      \"method\": \"cDNA cloning, structural analysis, and functional expression in B cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with functional validation, foundational paper with >2000 citations\",\n      \"pmids\": [\"3491322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"IL-6 (IFN-beta 2/BSF-2) was shown to be the monocyte-derived hepatocyte-stimulating factor that drives the major acute-phase protein response in liver cells, establishing the liver as a primary physiologic target of IL-6.\",\n      \"method\": \"Neutralizing antibody experiments, recombinant protein treatment of HepG2 cells and primary rat hepatocytes, Northern analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with recombinant protein plus antibody-blocking, replicated across cell types; >1700 citations\",\n      \"pmids\": [\"2444978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"IL-6 signaling requires its receptor (IL-6-R, 80 kDa) to trigger association with a second non-ligand-binding membrane glycoprotein, gp130; this association is temperature-dependent (occurs at 37°C but not 0°C) and a soluble IL-6-R lacking transmembrane/intracytoplasmic domains can associate with gp130 extracellularly and mediate IL-6 signaling (trans-signaling).\",\n      \"method\": \"Co-immunoprecipitation, binding assays, transfection of mutant receptors in murine cells\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — receptor association demonstrated by biochemical and functional assays with domain-deletion mutants; >1300 citations\",\n      \"pmids\": [\"2788034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"IL-1β stimulation of human endothelial cells markedly increases (10-15-fold) IL-6 production, confirmed by anti-IL-6 antibody inhibition of hybridoma growth factor activity and Northern blot analysis of IL-6 mRNA; IL-6 itself did not alter endothelial cell function (proliferation, procoagulant activity, prostacyclin, or PMN adhesion).\",\n      \"method\": \"Bioassay (HGF on 7TD1 cells), neutralizing antibodies, Northern blot, functional assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a well-controlled study; >580 citations\",\n      \"pmids\": [\"2783442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"IL-6 is produced by osteoblasts in response to local bone-resorbing agents (IL-1α, IL-1β, TNF-α, LPS) and itself induces bone resorption by increasing osteoclast numbers, and acts cooperatively with IL-1α at suboptimal concentrations.\",\n      \"method\": \"RT-PCR/Northern blot for IL-6 mRNA, 45Ca release assay, osteoclast counting in histological sections\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in primary cells and cell lines; >920 citations\",\n      \"pmids\": [\"2121824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"gp130 was molecularly cloned (918 amino acids, single transmembrane domain, extracellular fibronectin type III modules). gp130 alone does not bind IL-6 but co-transfection with IL-6-R cDNA generates high-affinity IL-6 binding sites. gp130 associates with the IL-6/soluble IL-6-R complex extracellularly and transduces the growth signal.\",\n      \"method\": \"cDNA cloning, binding assays, co-transfection experiments, growth signal transduction assay in IL-3-dependent cell line\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — molecular cloning with functional reconstitution; >1250 citations\",\n      \"pmids\": [\"2261637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Oncostatin M (OncM) stimulates IL-6 production in human endothelial cells in a time- and dose-dependent manner (>10-fold at 6 h), associated with a 7-fold increase in IL-6 mRNA; IL-1α and TNF-α also induce IL-6 in these cells; TNF-α but not IL-1α synergizes with OncM for IL-6 production.\",\n      \"method\": \"Immunoassay (IL-6 ELISA), Northern blot, receptor binding assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple assays in a single study\",\n      \"pmids\": [\"1918953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"gp130 and LIF receptor β constitutively associate with JAK/TYK kinases (JAK1, JAK2, TYK2); ligand-induced dimerization of the receptor β components activates these kinases. The CNTF cytokine family receptors utilize all known members of the JAK-TYK family but induce distinct phosphorylation patterns.\",\n      \"method\": \"Co-immunoprecipitation, kinase activation assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — co-immunoprecipitation and kinase activation assays; >920 citations; established mechanistic basis of IL-6/gp130 signaling\",\n      \"pmids\": [\"8272873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"IL-6 induces VEGF expression in multiple cell lines (Northern blot); this induction is mediated not only by promoter DNA elements but also through specific motifs in the 5'-UTR of VEGF mRNA, suggesting IL-6 drives angiogenesis indirectly via VEGF induction.\",\n      \"method\": \"Northern blot analysis, transient transfection/reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Northern blot plus functional transfection reporter assays; >890 citations\",\n      \"pmids\": [\"8557680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"In vivo, the soluble IL-6 receptor (sIL-6R) dramatically hypersensitizes cells to IL-6 by prolonging IL-6 plasma half-life and extending the acute phase response; the IL-6/sIL-6R complex (but not IL-6 alone) drives massive extramedullary hematopoiesis in liver and spleen, demonstrating a biologically distinct activity of the trans-signaling complex.\",\n      \"method\": \"Transgenic mouse models expressing human IL-6, human sIL-6R, or both; acute-phase protein measurements; histology\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic/transgenic animal model with multiple functional readouts\",\n      \"pmids\": [\"9052874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Repression of the IL-6 gene in MCF-7 breast carcinoma cells is associated with hypermethylation of the IL-6 gene; treatment with 5-aza-2'-deoxycytidine (a demethylating agent) restores IL-6 expression, establishing DNA methylation as a mechanism of IL-6 transcriptional repression.\",\n      \"method\": \"Northern blot, 5-aza-dC treatment, methylation analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological demethylation correlated with gene re-expression; single lab\",\n      \"pmids\": [\"10329438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-6 produced by contracting skeletal muscle accounts for the exercise-induced rise in plasma IL-6: direct arterial-femoral venous difference measurements showed net IL-6 release only from the exercising (not resting) leg, with IL-6 production rates of ~6.8 ng/min per kg active muscle.\",\n      \"method\": \"Arterial-femoral venous difference measurements, ultrasound Doppler blood flow, ELISA\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct measurement of net cytokine release from exercising muscle in vivo; >780 citations\",\n      \"pmids\": [\"11080265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"During turpentine-induced inflammation, CRH is required for normal ACTH response and for adrenal IL-6 expression. Loss of CRH paradoxically increases plasma IL-6 from non-adrenal sources, revealing that IL-6 release during inflammation is CRH-dependent and IL-6 can compensate for CRH deficiency effects on food intake.\",\n      \"method\": \"Crh−/− and Crh−/−/IL-6−/− mouse models, ELISA, in situ hybridization\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout combined with biochemical measurements\",\n      \"pmids\": [\"11602623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-6 promotes Th2 differentiation by activating NFAT-mediated IL-4 transcription in naïve CD4+ T cells, while simultaneously inhibiting Th1 differentiation by upregulating SOCS-1 to interfere with IFNγ signaling — two independent molecular mechanisms.\",\n      \"method\": \"T cell differentiation assays, NFAT reporter assays, SOCS-1 expression analysis\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal mechanisms identified; single lab\",\n      \"pmids\": [\"12431386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IL-6 induces anti-inflammatory responses in humans in vivo: recombinant IL-6 infusion (mimicking exercise levels, ~140 pg/mL) elevated plasma IL-1ra and IL-10, increased cortisol, and caused neutrocytosis and lymphopenia, without inducing TNF-α.\",\n      \"method\": \"Randomized human infusion study, ELISA cytokine measurements, leukocyte counts\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — controlled human intervention study demonstrating direct anti-inflammatory cytokine induction; >810 citations\",\n      \"pmids\": [\"12857678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IL-6 induces insulin resistance in 3T3-L1 adipocytes through long-term inhibition of IRS-1, GLUT-4, and PPARγ gene transcription (reducing IRS-1 protein and insulin-stimulated glucose transport), without increasing pS-307 of IRS-1 or JNK activation (unlike TNF-α).\",\n      \"method\": \"Cell culture experiments with recombinant IL-6, Western blot, gene expression analysis, glucose transport assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays in single lab; >810 citations\",\n      \"pmids\": [\"12952969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation via gp130: IL-6-knockout mice had increased mature DCs, and knockin mice with gp130 STAT3-signaling defects (gp130FxxQ/FxxQ) showed impaired IL-6-mediated suppression of LPS-induced DC maturation; STAT3 phosphorylation in DCs was regulated by IL-6 in vivo.\",\n      \"method\": \"IL-6 knockout and gp130 knockin mice, flow cytometry, T cell activation assays, STAT3 phosphorylation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic mouse models with defined pathway mutations; >400 citations\",\n      \"pmids\": [\"15356132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-6 directly inhibits primary hepatocyte proliferation via a p21cip1-dependent mechanism (loss of p21cip1 abolishes IL-6-mediated inhibition), while indirectly stimulating proliferation by inducing HGF production from non-parenchymal cells; SOCS3 negatively regulates these effects.\",\n      \"method\": \"Primary mouse hepatocyte culture, p21cip1-knockout cells, co-culture assays, SOCS3+/- mice, in vivo liver regeneration assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout epistasis plus in vitro and in vivo assays; multiple orthogonal methods\",\n      \"pmids\": [\"16288983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-6 rapidly increases AMPK activity in skeletal muscle, and IL-6-stimulated increases in fatty acid oxidation, basal/insulin-stimulated glucose uptake, and GLUT4 translocation to the plasma membrane are abrogated by dominant-negative AMPK, placing AMPK downstream of IL-6 signaling in muscle metabolism.\",\n      \"method\": \"IL-6 infusion/treatment of myotubes, AMPK activity assays, GLUT4 translocation, dominant-negative AMPK infection\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — dominant-negative epistasis in cell culture with functional metabolic readouts\",\n      \"pmids\": [\"17956334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IL-6 directly regulates hepcidin expression through induction of STAT3, which then binds the hepcidin promoter; STAT3 is both necessary and sufficient for the IL-6 responsiveness of the hepcidin promoter.\",\n      \"method\": \"STAT3 knockout/siRNA, promoter reporter assays, ChIP, ELISA\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter reporter assays plus ChIP plus loss-of-function; >750 citations\",\n      \"pmids\": [\"16835372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Sleep enhances IL-6 trans-signaling capacity in healthy humans by selectively increasing concentrations of the proteolytically cleaved sIL-6R variant (not the differentially spliced form or mIL-6R density or sgp130), thus widening the spectrum of IL-6 target cells during sleep.\",\n      \"method\": \"Controlled sleep/wake study in humans, plasma sIL-6R/sgp130 measurement, mIL-6R flow cytometry, IL-6-producing monocyte analysis\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — controlled crossover design with multiple receptor measurements; single lab\",\n      \"pmids\": [\"16912152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Persistent DNA damage signaling (DSBs marked by γH2AX foci) triggers IL-6 secretion as part of the senescence-associated secretory phenotype (SASP); this requires the DDR proteins ATM, NBS1, and CHK2 (but not p53 or pRb), and ATM-dependent IL-6 promotes cancer cell invasiveness in a paracrine manner.\",\n      \"method\": \"shRNA knockdown of DDR proteins, IL-6 ELISA, invasion assays, immunofluorescence\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic loss-of-function with functional readouts, replicated; >1750 citations\",\n      \"pmids\": [\"19597488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Transient Src oncoprotein activation triggers an NF-κB-mediated inflammatory circuit that directly activates Lin28, which reduces let-7 microRNA levels; let-7 directly represses IL-6 translation, so its loss leads to elevated IL-6, which activates STAT3; STAT3 is necessary for cell transformation, and IL-6 activates NF-κB completing a positive feedback loop maintaining stable transformation.\",\n      \"method\": \"shRNA, reporter assays, overexpression, miRNA inhibitors, STAT3 inhibition, mammosphere formation assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal genetic and molecular tools establishing pathway; >1200 citations\",\n      \"pmids\": [\"19878981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-6 classical signaling (via membrane-bound IL-6R → gp130 dimerization → JAK activation → SHP-2/Ras/MAPK and STAT3 phosphorylation → nuclear translocation) mediates regenerative/anti-inflammatory activities, while trans-signaling (via soluble IL-6R/gp130 complex) mediates pro-inflammatory responses.\",\n      \"method\": \"Review synthesizing biochemical pathway analysis; signaling domain experiments, chimeric receptor studies\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — synthesis of structural/biochemical pathway data from multiple labs; >2400 citations\",\n      \"pmids\": [\"21296109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-6 trans-signaling (via soluble IL-6R) activates STAT3/SOCS3 in pancreatic ductal cells, and this signaling is required for progression of KrasG12D-driven pancreatic intraepithelial neoplasias (PanINs) to pancreatic ductal adenocarcinoma; myeloid cells are the source of IL-6 that activates pancreatic STAT3.\",\n      \"method\": \"Genetic mouse models (Kras G12D; IL-6 trans-signaling deficient; Socs3 knockout), immunohistochemistry, STAT3 phosphorylation analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic mouse models with clear pathway epistasis; >710 citations\",\n      \"pmids\": [\"21481788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-6 stimulates GLP-1 secretion from intestinal L cells and pancreatic α cells; in α cells, IL-6 increases GLP-1 production by upregulating proglucagon and prohormone convertase 1/3 expression, thereby improving insulin secretion and glycemia.\",\n      \"method\": \"IL-6 administration in mice/humans, GLP-1 ELISA, proglucagon/PC1-3 mRNA and protein expression, in vitro L cell and α cell experiments\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic experiments in vitro and in vivo with molecular pathway identification; >730 citations\",\n      \"pmids\": [\"22037645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IL-6 combined with TGF-β synergistically promotes proteasome-dependent FOXP3 protein degradation (post-translational), reducing Treg activity; MG132 (proteasome inhibitor) blocked this effect; IL-6/TGF-β upregulated IL-6R expression without affecting FOXP3 mRNA stability.\",\n      \"method\": \"FOXP3 overexpression model, Western blot, proteasome inhibitor (MG132), flow cytometry\",\n      \"journal\": \"International journal of clinical and experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pharmacological inhibitor approach, mechanistic follow-up partial\",\n      \"pmids\": [\"22977658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOCS3 inhibits IL-6 signaling by binding simultaneously to gp130 and JAK1/JAK2/TYK2 (but not JAK3) via a 'GQM' motif in the JAK kinase domain; SOCS3 inhibits JAK activity in an ATP-independent manner by partially occluding the kinase substrate-binding groove with its kinase inhibitory region.\",\n      \"method\": \"Biochemical/structural studies, domain mutagenesis, binding assays\",\n      \"journal\": \"Seminars in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural and biochemical mechanistic data from multiple labs; synthesis of structural evidence\",\n      \"pmids\": [\"24418198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Tet2 selectively represses IL-6 transcription during inflammation resolution by recruiting Hdac2 to the Il6 promoter (independent of DNA methylation/hydroxymethylation); IκBζ targets Tet2 to the Il6 promoter; Tet2-deficient mice show elevated IL-6 and increased susceptibility to endotoxin shock and colitis.\",\n      \"method\": \"Tet2-knockout mice, ChIP assays, HDAC inhibitor experiments, Co-IP (Tet2-Hdac2), luciferase reporter assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including genetic models, ChIP, and Co-IP; >670 citations\",\n      \"pmids\": [\"26287468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-6 enhances osteocyte-mediated osteoclastogenesis by activating the JAK2-STAT3 pathway to upregulate RANKL expression in osteocyte-like MLO-Y4 cells; inhibition of JAK2 with AG490 suppressed pJAK2, RANKL expression, and osteoclast differentiation.\",\n      \"method\": \"RT-PCR, Western blot, TRAP staining/osteoclast formation assay, JAK2 inhibitor AG490\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway inhibition plus gene expression in vitro; single lab\",\n      \"pmids\": [\"28278513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Kdm6a (demethylase) promotes IL-6 transcription in macrophages by demethylating H3K27me3 at the IL-6 promoter in an enzymatic activity-dependent manner; this activity is downregulated via JNK pathway upon innate stimuli.\",\n      \"method\": \"Kdm6a knockdown/overexpression, ChIP-seq, H3K27me3 ChIP, enzymatic activity mutants in primary macrophages\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq and enzymatic mutant experiments in primary cells; single lab\",\n      \"pmids\": [\"28284523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Post-MI cardiac IL-6 is preferentially produced by cardiac fibroblasts; adenosine stimulates fibroblast IL-6 formation via adenosine receptor A2bR in a Gq-dependent manner; cardiac fibroblasts degrade extracellular ATP to adenosine but lack CD73, relying on T cell-derived adenosine for IL-6 regulation.\",\n      \"method\": \"Single-cell RNA-seq (mouse and human), RNAscope, qPCR, protein quantification in isolated cell types, A2bR pharmacology, CD4-CD73-/- mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq plus genetic mouse model plus receptor pharmacology; validated in human data\",\n      \"pmids\": [\"36943408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-6 activates autophagy through the IL-6/JAK2/BECN1 pathway: JAK2 directly phosphorylates BECN1 at Y333 upon IL-6 stimulation; Y333 phosphorylation is required for BECN1 activation and PI3KC3 complex formation, promoting chemotherapy resistance in colorectal cancer.\",\n      \"method\": \"Co-IP, in vitro kinase assay, site-directed mutagenesis (Y333), PI3KC3 complex immunoprecipitation, autophagy flux assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct kinase assay identifying phosphorylation site, mutagenesis validation, complex assembly assay\",\n      \"pmids\": [\"34131122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-6 induces Csf1r (CSF1R) expression in Tet2-deficient macrophages through enhanced STAT3 binding to the Csf1r promoter; IL-6 receptor antibody treatment reverses Tet2 clonal hematopoiesis-accelerated atherosclerosis by reducing monocytosis, lesional macrophage burden, and CSF1R expression.\",\n      \"method\": \"IL-6R antibody treatment in Tet2 CH mice, ChIP for STAT3 at Csf1r promoter, CSF1R inhibitor (PLX3397), mouse and human macrophage experiments\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP identifying direct STAT3-promoter binding plus genetic and pharmacological validation in vivo\",\n      \"pmids\": [\"37539077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In M2 macrophages, YY1 forms a liquid-liquid phase separation complex with p300, p65, and CEBPB that upregulates IL-6 through long-range chromatin interactions between an M2-specific IL-6 enhancer and the IL-6 promoter; IL-4/STAT6 pathway regulates YY1 expression.\",\n      \"method\": \"CRISPR-Cas9 KO, H3K27ac-ChIP-seq, YY1 ChIP-seq, LLPS assays, chromatin conformation (enhancer-promoter interaction), RNA-seq\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genomic and biochemical methods including ChIP-seq and LLPS assays\",\n      \"pmids\": [\"37094986\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-6, a 184-amino-acid four-helix bundle cytokine, signals by binding its membrane-bound IL-6Rα, triggering association with the signal-transducing subunit gp130, which dimerizes and constitutively-associated JAK kinases (JAK1, JAK2, TYK2) transphosphorylate gp130 tyrosines, engaging SHP-2/Ras/MAPK and STAT3 pathways; in trans-signaling, soluble IL-6Rα (shed by ADAM proteases) forms a complex with IL-6 that activates gp130 on cells lacking membrane IL-6Rα, broadly expanding IL-6's target cell repertoire; downstream STAT3 activation drives hepcidin expression, VEGF induction, dendritic cell maturation, Th17/Treg balance, osteoclastogenesis via RANKL upregulation, and pancreatic cancer progression, while SOCS3 terminates signaling by simultaneously binding JAK1/2/TYK2 and gp130; IL-6 transcription is regulated by epigenetic mechanisms including Tet2/Hdac2-mediated histone deacetylation (repression), Kdm6a-mediated H3K27me3 demethylation (activation), YY1 phase-separation complex-driven enhancer-promoter looping, and DNA methylation; JAK2 also directly phosphorylates BECN1 at Y333 to activate autophagy downstream of IL-6.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IL-6 is a pleiotropic cytokine that orchestrates innate and adaptive immune responses, inflammation resolution, bone remodeling, and cell fate decisions by signaling through a gp130-dependent receptor system via classical (membrane IL-6Rα) or trans-signaling (soluble IL-6Rα) modes, activating JAK–STAT3 and downstream effectors [PMID:9052874, PMID:29626088]. Transcription of IL-6 is tightly controlled by epigenetic mechanisms including Tet2/Hdac2-mediated histone deacetylation at the IL-6 promoter for repression, Kdm6a-dependent H3K27me3 demethylation for activation, and IκBζ/NF-κB-dependent transcriptional induction [PMID:26287468, PMID:28284523, PMID:19783680]. Downstream, IL-6–JAK2–STAT3 signaling drives context-specific gene programs — including RANKL and CSF1R induction for osteoclastogenesis and macrophage survival, BECN1 Y333 phosphorylation to activate autophagy, and NFAT-mediated Th2 polarization — while SOCS3 terminates signaling by simultaneously engaging gp130 and JAK kinases to occlude their substrate groove [PMID:28278513, PMID:37539077, PMID:34131122, PMID:12431386, PMID:24418198]. IL-6 also maintains dendritic cell immaturity via gp130–STAT3, inhibits Th2 airway inflammation in vivo, and functions as a paracrine factor from senescent cells required for in vivo cellular reprogramming [PMID:15356132, PMID:11034416, PMID:29280266].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"The discovery that soluble IL-6Rα forms a complex with IL-6 to activate gp130 on cells lacking membrane IL-6Rα established trans-signaling as a distinct signaling mode with unique in vivo biological outcomes such as extramedullary hematopoiesis.\",\n      \"evidence\": \"Transgenic mice co-expressing human IL-6 and soluble IL-6R vs. IL-6 alone, with acute phase protein and histological readouts\",\n      \"pmids\": [\"9052874\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of sIL-6R/IL-6/gp130 hexamer assembly not resolved\", \"Relative contributions of proteolytic vs. alternatively spliced sIL-6R in vivo unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that the IL-6 gene can be epigenetically silenced by promoter hypermethylation, with reactivation upon demethylation, showed that DNA methylation is a direct regulator of IL-6 expression in cancer cells.\",\n      \"evidence\": \"5-aza-2'-deoxycytidine treatment of MCF-7 cells with methylation analysis and Northern blot\",\n      \"pmids\": [\"10329438\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methylation mapped globally, not at single-CpG resolution\", \"Functional consequence of restored IL-6 on tumor behavior not assessed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Reciprocal gain- and loss-of-function genetic models showed that IL-6 suppresses Th2 airway inflammation independently of IFN-γ, revealing an anti-inflammatory role counter to its classical pro-inflammatory identity.\",\n      \"evidence\": \"IL-6 KO and CC10-IL-6 transgenic mice in OVA sensitization/challenge model\",\n      \"pmids\": [\"11034416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream molecular pathway by which IL-6 suppresses Th2 cytokines not fully defined\", \"Whether trans- vs. classical signaling mediates this effect unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"IL-6 was shown to promote Th2 differentiation via NFAT-dependent IL-4 production and independently suppress Th1 via SOCS1 upregulation, establishing dual molecular pathways for T helper polarization.\",\n      \"evidence\": \"In vitro CD4+ T cell differentiation, NFAT reporter assays, SOCS1 expression, cytokine neutralization\",\n      \"pmids\": [\"12431386\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Apparent contradiction with in vivo Th2-suppressive role needs resolution\", \"Direct STAT3 involvement in NFAT activation not dissected\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Genetic epistasis using gp130 knockin mice with selective signaling mutations demonstrated that IL-6 maintains dendritic cell immaturity specifically through the gp130–STAT3 axis, linking IL-6 to immune tolerance.\",\n      \"evidence\": \"IL-6 KO, gp130F759/F759 and gp130FxxQ/FxxQ knockin mice, STAT3 phosphorylation\",\n      \"pmids\": [\"15356132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target genes downstream of STAT3 that enforce DC immaturity not identified\", \"Whether trans-signaling contributes to DC regulation not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"IL-6 was found to exert opposing effects on hepatocyte proliferation — direct inhibition through p21cip1 induction and indirect promotion through HGF from nonparenchymal cells — with SOCS3 acting as a negative regulator of both.\",\n      \"evidence\": \"Primary hepatocytes, p21cip1 KO mice, co-culture, SOCS3 heterozygous mice, liver regeneration\",\n      \"pmids\": [\"16288983\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SOCS3 mechanism of action on p21cip1 pathway not molecularly resolved\", \"Relative contribution of each arm during liver regeneration in vivo unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of IκBζ (MAIL) as a transcriptional co-activator that binds NF-κB p50 to drive IL-6 promoter activity clarified how IL-6 is selectively induced among NF-κB target genes, linking to the earlier Tet2/IκBζ axis.\",\n      \"evidence\": \"Co-IP of MAIL-p50, luciferase promoter assay, siRNA knockdown in monocytes/THP-1\",\n      \"pmids\": [\"19783680\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Chromatin-level mechanism of IκBζ action at the IL-6 promoter not shown\", \"Specificity of IκBζ for IL-6 versus other NF-κB targets not fully delineated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Structural and biochemical dissection of SOCS3 revealed that it terminates IL-6 signaling by simultaneously binding gp130 and JAK1/JAK2/TYK2, occluding the kinase substrate groove via its KIR in an ATP-independent manner, with specificity determined by a GQM motif.\",\n      \"evidence\": \"Structural studies, biochemical binding assays, mutagenesis\",\n      \"pmids\": [\"24418198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full crystal structure of the ternary SOCS3–gp130–JAK complex not yet reported\", \"How SOCS3 is recruited to the activated complex in temporal sequence not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Tet2 was shown to repress IL-6 transcription by recruiting Hdac2 to the IL-6 promoter independently of its catalytic DNA demethylase activity, with IκBζ mediating specific promoter targeting — establishing a non-canonical epigenetic silencing mechanism for inflammation resolution.\",\n      \"evidence\": \"ChIP, Tet2 KO mice, phenotypic readouts (endotoxin shock, colitis susceptibility)\",\n      \"pmids\": [\"26287468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Tet2 is directed to IL-6 but not other inflammatory genes beyond IκBζ unclear\", \"Whether Hdac2 recruitment requires additional cofactors not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Three studies collectively expanded the downstream effector landscape: IL-6–JAK2–STAT3 upregulates RANKL in osteocytes to promote osteoclastogenesis, Kdm6a activates IL-6 transcription via H3K27me3 demethylation in macrophages, and IL-6 from senescent cells is required as a paracrine factor for in vivo OSKM reprogramming.\",\n      \"evidence\": \"Co-culture osteoclastogenesis with JAK2 inhibitor [PMID:28278513]; ChIP for H3K27me3 with Kdm6a demethylase-dead mutant [PMID:28284523]; Il6-mutant mice in OSKM reprogramming model [PMID:29280266]\",\n      \"pmids\": [\"28278513\", \"28284523\", \"29280266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Kdm6a and Tet2 operate on the same IL-6 promoter regions is unknown\", \"Direct STAT3 binding at RANKL promoter in osteocytes not confirmed by ChIP\", \"Signaling pathway from IL-6 to reprogramming factor activation not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The paradox of granulocyte unresponsiveness to IL-6 despite expressing IL-6Rα was resolved by showing that gp130 expression is lost during granulocyte maturation, establishing gp130 as the gating factor for IL-6 responsiveness.\",\n      \"evidence\": \"Flow cytometry and STAT3/STAT1 phosphorylation in mouse and human granulocytes and progenitors\",\n      \"pmids\": [\"29626088\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional or post-transcriptional mechanism of gp130 downregulation during granulopoiesis not identified\", \"Whether granulocyte-shed IL-6Rα contributes to trans-signaling not explored\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"IL-6 was directly linked to autophagy activation through JAK2-mediated phosphorylation of BECN1 at Y333, promoting PI3KC3 complex formation and chemotherapy resistance in colorectal cancer.\",\n      \"evidence\": \"In vitro kinase assay, Y333 mutagenesis, Co-IP, autophagy flux assays\",\n      \"pmids\": [\"34131122\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BECN1-Y333 phosphorylation occurs in non-cancer contexts not tested\", \"Structural basis for JAK2–BECN1 interaction unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Two studies defined new physiological circuits: IL-6–STAT3 induces CSF1R in Tet2-deficient macrophages to promote atherosclerosis (reversible by anti-IL-6R), and cardiac fibroblast IL-6 production post-MI is controlled by T cell-derived adenosine via A2bR–Gq signaling.\",\n      \"evidence\": \"STAT3 ChIP at Csf1r promoter with IL-6R antibody and CSF1R inhibitor in atherosclerosis model [PMID:37539077]; scRNA-seq in mouse/human hearts, CD4-CD73 conditional KO, A2bR pharmacology [PMID:36943408]\",\n      \"pmids\": [\"37539077\", \"36943408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the Tet2-loss/IL-6/CSF1R axis operates outside the hematopoietic compartment unclear\", \"Downstream signaling from A2bR–Gq to IL-6 transcriptional machinery in fibroblasts not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: how trans- versus classical signaling are differentially regulated at the tissue level to produce opposing immunological outcomes (e.g., Th2 promotion vs. suppression), what chromatin states integrate the Tet2/Hdac2 repressive and Kdm6a activating epigenetic inputs at the IL-6 locus, and whether the BECN1-Y333 autophagy axis is a general feature of IL-6 signaling or restricted to cancer contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No systematic mapping of trans- vs. classical signaling to distinct gene programs\", \"Integration of multiple epigenetic regulators at the IL-6 locus not studied simultaneously\", \"In vivo relevance of IL-6–BECN1 autophagy axis outside colorectal cancer untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 3, 4, 5, 7, 8, 10, 15, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 6, 13, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 3, 5, 7, 10, 16, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4, 9, 15, 16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 11, 12, 14]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"IL6R\",\n      \"IL6ST\",\n      \"JAK1\",\n      \"JAK2\",\n      \"STAT3\",\n      \"SOCS3\",\n      \"BECN1\",\n      \"TET2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"IL-6 is a pleiotropic four-helix-bundle cytokine that orchestrates acute-phase responses, immune cell differentiation, metabolic regulation, and tissue remodeling by engaging classical signaling through membrane-bound IL-6Rα/gp130 or trans-signaling through soluble IL-6Rα/gp130, both converging on JAK1/JAK2/TYK2-mediated activation of STAT3, SHP-2/Ras/MAPK, and AMPK pathways [PMID:2788034, PMID:8272873, PMID:21296109, PMID:17956334]. Classical signaling drives regenerative and anti-inflammatory programs—including hepatic acute-phase protein and hepcidin induction via STAT3 promoter binding, dendritic cell maturation control, and GLP-1 secretion from intestinal L cells—while trans-signaling preferentially mediates pro-inflammatory activities such as STAT3/SOCS3-dependent progression of Kras-driven pancreatic neoplasia and paracrine promotion of cancer cell invasiveness as part of the senescence-associated secretory phenotype [PMID:2444978, PMID:16835372, PMID:22037645, PMID:21481788, PMID:19597488]. IL-6 transcription is tightly regulated by epigenetic mechanisms including Tet2/Hdac2-mediated histone deacetylation at the IL-6 promoter, Kdm6a-catalyzed H3K27me3 demethylation, DNA methylation, and YY1/p300/p65/CEBPB phase-separation complexes that mediate enhancer–promoter looping [PMID:26287468, PMID:28284523, PMID:10329438, PMID:37094986]. Downstream, JAK2 directly phosphorylates BECN1 at Y333 to activate PI3KC3 complex-dependent autophagy, while SOCS3 terminates signaling by simultaneously engaging gp130 and JAK kinases to occlude the substrate-binding groove [PMID:34131122, PMID:24418198].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Molecular cloning of IL-6 (BSF-2) established it as a novel interleukin capable of driving B cell terminal differentiation into immunoglobulin-secreting cells, resolving the identity of a long-sought B cell stimulatory factor.\",\n      \"evidence\": \"cDNA cloning and functional expression in B cells\",\n      \"pmids\": [\"3491322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No receptor identified\", \"No signaling pathway known\", \"Range of target cell types unknown\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Demonstration that IL-6 is the monocyte-derived hepatocyte-stimulating factor driving the acute-phase protein response revealed the liver as a major physiologic target, expanding IL-6 function beyond B cell biology.\",\n      \"evidence\": \"Neutralizing antibody blockade and recombinant IL-6 treatment of HepG2 cells and primary hepatocytes\",\n      \"pmids\": [\"2444978\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of hepatocyte signaling unknown\", \"Receptor complex not yet defined\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Discovery that IL-6Rα must recruit gp130 for signal transduction, and that a soluble IL-6Rα ectodomain can mediate this association extracellularly, established the two-receptor model and the concept of trans-signaling.\",\n      \"evidence\": \"Co-immunoprecipitation, binding assays, and transfection of transmembrane-deletion mutants in murine cells\",\n      \"pmids\": [\"2788034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"gp130 not yet cloned\", \"Intracellular signaling cascade unknown\", \"Physiologic relevance of trans-signaling in vivo unproven\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Molecular cloning of gp130 and reconstitution of high-affinity IL-6 binding sites by co-transfection with IL-6Rα provided the structural basis for the signaling receptor complex and confirmed gp130 as the obligate signal transducer.\",\n      \"evidence\": \"cDNA cloning, co-transfection binding assays, and growth signal transduction assays in IL-3-dependent cells\",\n      \"pmids\": [\"2261637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinases coupled to gp130 unknown\", \"Downstream transcription factors not identified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification that gp130 constitutively associates with JAK1, JAK2, and TYK2, which are activated upon ligand-induced receptor dimerization, resolved the proximal kinase machinery of IL-6 signaling.\",\n      \"evidence\": \"Co-immunoprecipitation and kinase activation assays\",\n      \"pmids\": [\"8272873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"STAT activation downstream of JAKs not yet shown for IL-6 specifically\", \"Negative regulators unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Two advances defined downstream effector outputs and trans-signaling physiology: IL-6 was shown to induce VEGF expression via promoter and 5′-UTR elements (linking IL-6 to angiogenesis), and transgenic mouse studies demonstrated that the IL-6/sIL-6R complex dramatically extends IL-6 half-life and drives extramedullary hematopoiesis not achievable by IL-6 alone.\",\n      \"evidence\": \"Northern blot/reporter assays for VEGF induction; transgenic mouse models with human IL-6 and sIL-6R\",\n      \"pmids\": [\"8557680\", \"9052874\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"STAT3 not yet directly linked to specific IL-6 gene targets\", \"Mechanism of sIL-6R shedding unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that IL-6 gene silencing in breast carcinoma cells is reversed by demethylation agents established DNA methylation as an epigenetic mechanism controlling IL-6 transcription.\",\n      \"evidence\": \"5-aza-2′-deoxycytidine treatment with Northern blot and methylation analysis in MCF-7 cells\",\n      \"pmids\": [\"10329438\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific CpG sites not mapped\", \"Methyltransferases responsible not identified\", \"Generalizability to non-cancer cells uncertain\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Direct arterio-venous measurements across exercising human muscle proved that contracting skeletal muscle is a major source of circulating IL-6, establishing IL-6 as an exercise-released myokine.\",\n      \"evidence\": \"Arterial-femoral venous difference with Doppler blood flow and ELISA in exercising humans\",\n      \"pmids\": [\"11080265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling triggering muscle IL-6 release unknown\", \"Metabolic targets of exercise-derived IL-6 not fully defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Controlled human infusion studies showed IL-6 at exercise-relevant concentrations induces anti-inflammatory mediators (IL-1ra, IL-10, cortisol) without TNF-α, while parallel in vitro work demonstrated IL-6 causes insulin resistance in adipocytes through transcriptional suppression of IRS-1 and GLUT-4, revealing context-dependent metabolic and immune effects.\",\n      \"evidence\": \"Randomized human IL-6 infusion with cytokine ELISA; recombinant IL-6 treatment of 3T3-L1 adipocytes with Western blot and glucose transport assays\",\n      \"pmids\": [\"12857678\", \"12952969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway mediating adipocyte insulin resistance not fully delineated\", \"In vivo adipose tissue effects not confirmed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Genetic dissection using IL-6−/− and gp130 STAT3-signaling-deficient knockin mice demonstrated that IL-6 regulates dendritic cell maturation in vivo through gp130-mediated STAT3 activation, placing STAT3 as a critical node for IL-6's immunomodulatory functions.\",\n      \"evidence\": \"IL-6 knockout and gp130FxxQ/FxxQ knockin mice with flow cytometry and STAT3 phosphorylation analysis\",\n      \"pmids\": [\"15356132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target genes downstream of STAT3 in DCs not cataloged\", \"Contribution of trans- vs. classical signaling in DC regulation not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"ChIP and promoter-reporter studies showed IL-6 directly activates hepcidin transcription through STAT3 binding to the hepcidin promoter, establishing the molecular mechanism by which IL-6 drives hypoferremia of inflammation.\",\n      \"evidence\": \"STAT3 knockout/siRNA, ChIP at hepcidin promoter, reporter assays\",\n      \"pmids\": [\"16835372\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of IL-6 vs. BMP pathway to hepcidin not quantified\", \"Role of trans-signaling at the hepcidin locus not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Two studies converged to place IL-6 at the center of oncogenic and senescence-associated feedback circuits: persistent DNA damage signaling (ATM/NBS1/CHK2-dependent) drives IL-6 secretion in the SASP to promote paracrine cancer invasiveness, while an NF-κB→Lin28→let-7 axis derepresses IL-6 translation, enabling IL-6/STAT3/NF-κB positive feedback that maintains Src-initiated transformation.\",\n      \"evidence\": \"shRNA knockdown of DDR proteins with invasion assays; miRNA inhibitors, reporter assays, and mammosphere formation\",\n      \"pmids\": [\"19597488\", \"19878981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of IL-6 vs. other SASP cytokines to invasiveness not isolated\", \"In vivo validation of NF-κB/Lin28/let-7/IL-6 loop limited\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic epistasis in Kras-driven pancreatic cancer models demonstrated that myeloid-derived IL-6 activates STAT3/SOCS3 in ductal cells via trans-signaling and is required for PanIN progression to adenocarcinoma, providing the first in vivo genetic evidence that trans-signaling drives a specific cancer type.\",\n      \"evidence\": \"KrasG12D mice crossed with IL-6 trans-signaling–deficient and Socs3-knockout models; STAT3 phosphorylation immunohistochemistry\",\n      \"pmids\": [\"21481788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific IL-6 target genes in ductal transformation not identified\", \"Therapeutic targeting of trans-signaling not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"IL-6 was shown to stimulate GLP-1 production from intestinal L cells and pancreatic α cells by upregulating proglucagon and prohormone convertase 1/3, linking IL-6 to incretin-mediated glucose homeostasis.\",\n      \"evidence\": \"IL-6 administration in mice and humans, GLP-1 ELISA, gene/protein expression in L cells and α cells\",\n      \"pmids\": [\"22037645\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediaries (STAT3 vs. MAPK) in L/α cells not resolved\", \"Chronic vs. acute IL-6 effects on incretin axis not distinguished\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Tet2 was identified as a selective transcriptional repressor of IL-6 that recruits Hdac2 to the IL-6 promoter independently of its DNA demethylase activity; IκBζ directs Tet2 to the locus, and Tet2 loss elevates IL-6 and worsens endotoxin shock and colitis.\",\n      \"evidence\": \"Tet2-knockout mice, Tet2–Hdac2 co-IP, ChIP at IL-6 promoter, HDAC inhibitor experiments, luciferase reporters\",\n      \"pmids\": [\"26287468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Tet2 represses IL-6 in non-myeloid cells unknown\", \"Crystal structure of Tet2–Hdac2 complex lacking\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Multiple layers of IL-6 regulation and effector function were refined: Kdm6a promotes IL-6 transcription by demethylating H3K27me3 at the promoter; IL-6 activates JAK2/STAT3 to upregulate RANKL in osteocytes, driving osteoclastogenesis; and SOCS3 terminates IL-6 signaling by simultaneously binding gp130 and JAK kinases to occlude the substrate-binding groove.\",\n      \"evidence\": \"ChIP-seq and enzymatic mutants in macrophages; JAK2 inhibitor in osteocyte-like cells; structural/biochemical domain analysis of SOCS3\",\n      \"pmids\": [\"28284523\", \"28278513\", \"24418198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of Kdm6a vs. Tet2 in setting IL-6 transcription threshold not tested\", \"Structural basis of SOCS3 specificity for gp130 over other cytokine receptors not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of BECN1 Y333 as a direct JAK2 phosphorylation substrate upon IL-6 stimulation revealed a non-canonical branch of IL-6 signaling that activates autophagy via PI3KC3 complex assembly, contributing to chemotherapy resistance.\",\n      \"evidence\": \"In vitro kinase assay, site-directed mutagenesis of BECN1 Y333, PI3KC3 complex immunoprecipitation, autophagy flux assays in colorectal cancer cells\",\n      \"pmids\": [\"34131122\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BECN1 Y333 phosphorylation occurs downstream of trans- vs. classical signaling not tested\", \"In vivo validation in animal tumor models limited\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Two studies addressed IL-6 transcriptional control and therapeutic targeting: YY1 forms liquid-liquid phase separation condensates with p300/p65/CEBPB to drive enhancer–promoter looping at the IL-6 locus in M2 macrophages, and IL-6R antibody blockade reverses Tet2-deficiency-driven atherosclerosis by reducing STAT3 binding at the Csf1r promoter.\",\n      \"evidence\": \"CRISPR-KO, ChIP-seq, LLPS assays, and chromatin conformation studies; IL-6R antibody treatment in Tet2 CH mice with STAT3 ChIP at Csf1r\",\n      \"pmids\": [\"37094986\", \"37539077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YY1 LLPS mechanism generalizes to other IL-6-producing cell types unknown\", \"Long-term safety and efficacy of IL-6R blockade in clonal hematopoiesis patients not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include how classical and trans-signaling are quantitatively balanced in specific tissues, the full repertoire of direct STAT3 target genes in different IL-6-responsive cell types, and whether the JAK2/BECN1 autophagy axis operates in physiologic (non-cancer) contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specific quantitative balance of classical vs. trans-signaling\", \"Complete catalog of direct IL-6/STAT3 target genes across cell types\", \"Physiologic relevance of JAK2-BECN1 autophagy outside cancer\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [13, 16, 17, 22, 24, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 9, 11, 14, 20, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 13, 14, 16, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 5, 7, 19, 23, 24, 27, 32]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [22, 24, 32]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [32]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 28, 30, 34]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [15, 18, 25]}\n    ],\n    \"complexes\": [\n      \"IL-6/IL-6Rα/gp130 hexameric signaling complex\",\n      \"IL-6/sIL-6Rα trans-signaling complex\"\n    ],\n    \"partners\": [\n      \"IL6R\",\n      \"IL6ST\",\n      \"JAK1\",\n      \"JAK2\",\n      \"TYK2\",\n      \"STAT3\",\n      \"SOCS3\",\n      \"BECN1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}